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Abstract 
This thesis is composed of three different projects, and aims to predict substrates which transported 
by transmembrane proteins, understand the effects caused by copy number alterations (CNAs) on 
target proteins of antineoplastic (AN) agents, and on the genes in antineoplastic resistance pathways 
in cancer patients. In the first project, we propose a computational method to classify membrane 
transporters from three organisms (Escherichia coli, Saccharomyces cerevisiae and Homo sapiens) 
according to their transported substrates. Our method focuses on neighboring genes that show high 
co-expression with query gene. Then, we identified frequent gene ontology (GO) terms among these 
co-expressed neighbors and used a support vector machine classifier to annotate the substrate 
specificity of the query gene. The second project analyses CNAs and clinical data of 31 tumor types 
from The Cancer Genome Atlas (TCGA). We found that the genome sequences of tumor patients 
generally contain more recurrently deleted CNAs than recurrently amplified CNAs. We observed 
certain signs of apparently compensating effects of CNAs. The third project continues the idea of 
chemoresistance as suggested in the second one. This project utilized TCGA CNAs data from both 
normal and tumor tissues. We found that the genome sequences of tumor tissues contain more 
recurrently amplified CNAs of genes in cancer antineoplastic resistance pathways than normal 
tissues.  
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Zusammenfassung 
Diese Arbeit besteht aus drei verschiedenen Projekten, die darauf abzielen Substrate die von 
Transmembranproteinen transportiert werden vorherzusagen, die Auswirkungen sog. 
Kopienzahlvariationen (CNAs) sowohl auf Zielproteine von Antineoplastischen Medikamenten als 
auch auf die zugehörigen Gene in den entsprechenden Resistenzwegen von Krebspatienten zu 
verstehen. Im ersten Projekt wird eine computergestützte Methode zur Klassifizierung von 
Transmembrantransportern dreier Organismen (Escherichia coli, Saccharomyces cerevisiae und 
Homo sapiens) anhand der von ihnen transportierten Substrate vorgestellt. Im zweiten Projekt 
wurden CNAs und klinische Daten von 31 Tumorarten die aus dem Cancer Genome Atlas (TCGA) 
stammen analysiert. Dabei stellte sich heraus, daß die genomischen Sequenzen von Tumorpatienten 
im allgemeinen mehr wiederkehrend deletierte CNAs aufweisen als wiederkehrend amplifizierte 
CNAs. Ebenfalls beobachtet wurden bestimmte Anzeichen für offensichtlich kompensatorische 
Effekte durch CNAs. Wie im vorgehenden Projekt wurde auch im dritten Teil der Arbeit die Idee 
der Chemoresistenz weiterverfolgt. Hierbei wurden CNA-Daten von normalem Gewebe, als auch 
von Tumorgewebe aus dem TCGA verwendet. Dabei wurde festgestellt, daß die genomischen 
Sequenzen von Tumorgewebe mehr wiederkehrend amplifizierte CNAs von Genen aufweisen, 
welche sich in Resistenzwegen von Antineoplastica befinden, als dies in normalem Gewebe der 
Fall ist.  
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Chapter 1 Introduction 
 
1.1 Introduction 
Since the discovery of deoxyribonucleic acid (DNA) in 1869 [1], our knowledge about this genetic 
material has been increasing rapidly. The 1950s can be considered as the start of a digital revolution 
of genomic data with the appearance of the digital computer [2], and the correct molecule structure 
of DNA proposed by James D. Watson and Francis Crick [3]. In the 1970s, the sequencing method 
by Sanger and personal computer accelerated the generation of sequencing data [4], [5]. This 
required new methods and tools for storing and processing data. Another need for sharing of 
sequencing data also arose in the 1990s when the Internet became more popular [6]. From this point, 
more and more database and computational tools have been online available. The next generation 
sequencing, a rapid large-scale DNA sequencing technology with relatively low cost [7], has made 
the need of new powerful computational tools become more urgent in the mid of the 2000s. The 
increasing amount of genomic data, the decreasing cost of data generation, and the success of 
computational techniques such as machine learning give us an opportunity to understand better 
genomic diseases and to find out new effective treatments. This thesis serves to improve our 
understanding of the genes encode transmembrane proteins, and the genomic copy number 
alterations in cancer patients. 
1.2 Motivation 
Proteins play a vital role in biological processes (e.g. catalyze reactions, transport molecules such 
as oxygen) [8]. A large portion of proteins are membrane proteins. According to Krogh et al. [9], 
about 21% of the Escherichia coli genes encode transmembrane proteins. The corresponding 
numbers are 21% in Saccharomyces cerevisiae, 30% in Caenorhabditis elegans and 20% in 
Arabidopsis thaliana. In Homo sapiens, membrane transporters comprise the second largest protein 
family next to G-protein coupled receptors. However, it is experimentally hard to identify their 
substrate specificities [10]. To address this problem, many computational methods were developed. 
Previously, substrate specificities of membrane transporters have been predicted, for example, 
based on sequence homology [11] and amino acid composition [12]–[14]. Meta-methods that 
combine different features for functional annotation often gave improved performance compared 
to single-feature methods. For example, Yayun Hu et al. used four sequence features including 
amino acid composition, composition, transition and distribution properties, position-specific 
scoring matrices, and biochemical properties to annotate the substrate specificity of ATP-binding 
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cassette (ABC) transporters [15]. They reported an accuracy of 88% to distinguish between four 
classes of ABC transporters. Still, it is worthwhile to characterize the benefits of individual features 
before combining them with others. 
Transmembrane proteins play important roles, especially in mediating the interaction 
between cells and their surroundings. Thus, membrane proteins are important targets for drugs 
(about 60% of all modern medical drugs [16]). These proteins also participate in drug resistance, 
e.g. MDR1 and MDR2 play important role in increasing drug efflux from cancer cell [17]. The drug 
targets, in general, can also resist to the drug by being mutated. Because of this relationship between 
drug targets and drug resistance, we would like to explore the characters of target genes of 
antineoplastic agents and the genes belong to antineoplastic resistance pathways. We retrieved 
cancer data from The Genome Cancer Atlas (TCGA), drugs targets from Drugbank, and four 
antineoplastic resistance pathways from Kyoto Encyclopedia of Genes and Genomes (KEGG). 
TCGA includes data for more than 30 cancer types. For each cancer type, data was organized into 
seven categories (Raw Sequencing Data, Transcriptome Profiling, Simple Nucleotide Variation, 
Copy Number Variation, Deoxyribonucleic acid (DNA) Methylation, Clinical, Biospecimen). In 
our work, we only used copy number variation and clinical data. 
1.3 Contributions 
Chapter 3 and 4 of this thesis are based on manuscripts that were already published. Chapter 5 has 
been prepared as a manuscript for submission. 
 Chapter 3: Tran, V.H., Barghash, A., Helms, V., (2018) Journal of Proteomics & 
Bioinformatics, V. 11, p. 868-874, doi: 10.4172/jpb.1000468. Annotating the function of 
protein-coding genes based on Gene Ontology terms of neighboring co-expressed genes. 
 Chapter 4: Tran, V.H., Kiemer, A., Helms, V., (2018) Cancer Genomics & Proteomics, V. 
15, p. 365-378,doi: 10.21873/cgp.20095 . Copy number alterations in tumor genomes 
deleting antineoplastic drug targets partially compensated by complementary amplifications 
 Chapter 5: Tran, V.H., Helms, V., Tumor genomes frequently contain amplified resistance 
genes prior to treatment (manuscript under preparation) 
1.4 Thesis organization 
The structure of the thesis as follows: 
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 Chapter 2 provides a general introduction to biological background (e.g. genome, gene 
expression, operon, protein) and computational methods (e.g. SVM classification, some 
statistical tests) used in this thesis. 
 Chapter 3 introduces a novel method for annotating the function of transmembrane proteins 
based on Gene Ontology terms and gene expression data. 
 Chapter 4 analyzes the effect of CNAs of target proteins of antineoplastic agents. 
 Chapter 5 compares the effects of CNAs in normal tissues and in tumor tissues on genes in 
four antineoplastic resistant pathways. 
 Chapter 6 summarizes the results of three projects and provides conclusions with regard to 
the aims of the studies and contribution made. 
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Chapter 2 Biological background and computational methods 
 
2.1 Genes and Genomes 
2.1.1 Genome organization 
Deoxyribonucleic acid (DNA), the genetic material of a cell, was first isolated by Friedrich 
Miescher, a Swiss physician, in 1869. He named it as “nuclein” because DNA resided inside the 
nuclei of eukaryotic cells [1]. More than eighty years after the existence of DNA was discovered, 
in 1953, James Watson and Francis Crick proposed the first correct structural model of DNA [3]. 
A macromolecule DNA consists of a long chain of connected nucleotides. Each nucleotide contains 
a nitrogen-containing nucleobase, a sugar (deoxyribose), and a phosphate group. There are four 
types of nucleotides discriminated by their nitrogen bases: cytosine (C), guanine (G), adenine (A) 
or thymine (T). Nucleobases are classified into two types: the purines (A and G), and the 
pyrimidines (C and T) [3]. As shown in Figure 2.1, a molecule is composed of two chains (made 
up of nucleotides) which coil around each other to form a double helix. The nucleotides are linked 
to each other to form a chain by covalent bonds between the sugar of one nucleotide and the 
phosphate of the next. The double-strand DNA are then formed by binding of 2 chains using 
hydrogen bonds between nitrogenous bases (A with T and C with G) [18]. 
 
Figure 2.1 DNA structure. Image was taken from [18] 
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DNA does not only resides inside the nucleus. DNA is also located in mitochondria and is 
then named mitochondrial DNA. In human, the 16,569 base pairs of mitochondrial DNA encode 
for only 37 genes [19]. In prokaryotes, the species that have no nuclei, in Escherichia coli for 
example, DNA forms a single circular chromosome packaged within the cell nucleoid [20], [21]. 
In eukaryotes, 145-147 base pairs of double-stranded DNA may wrap around a histone 
octamer and form a complex called nucleosome [22], [23]. Nucleosomes are then connected via 10-
80 base pairs of linker DNA. Linked nucleosomes are the primary structure of chromatin. Next, this 
primary structure is coiled into 30-nanometer fibers [24]. Figure 2.2 shows that the higher-order 
structures of chromatin are formed until finally a chromosome is created. This DNA packing 
process helps a human cell to store about 2 meters of DNA into its nucleus [24]. A nucleosome is 
a basic repeating structural unit of chromatin [25] in eukaryotes. Most prokaryotes (except species 
in the domain Archaea), however, do not have histone proteins. Thus, prokaryotes (e.g. Escherichia 
coli) use supercoiling as a method to compress their DNA into smaller space (see Figure 2.3) [26].  
 
Figure 2.2 Chromosome structure. This image was taken from [24] 
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Figure 2.3 Supercoiled chromosome of Escherichia coli. This image was taken from [26] 
2.1.2 Copy number variations 
In eukaryotes, the genomes of species are replicated (duplicated) through mitosis. The replication 
can be blocked if the DNA is damaged [27]. The damages may incur due to effects of both 
endogenously arising compounds (e.g. reactive oxygen species) and by exogenous agents (e.g. 
mutagenic chemicals, radiation)  [28]. One of the most cytotoxic forms of damage is double-strand 
breaks (DSBs). The good news is that DSBs can be repaired by different mechanisms, including 
homologous recombination (HR) and nonhomologous end-joining [29]. HR repairs damaged DNA 
sequence by using another identical sequence from homologous chromosome. However, the 
replacement sequence may have segment duplications, HR may lead to changes of the chromosome 
structure [30]. In contrast, nonhomologous recombination mechanisms use only microhomology of 
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a few complementary base pairs or no homology, and has the possibility of changing the structure 
of chromosomes [30]. 
Copy number changes are a type of structural variant involving alterations in the number of 
copies of specific large regions of DNA (thousands of nucleotides [>1 kb]), which can either be 
deleted or duplicated [31]. When these changes occur in germline cells, they are referred to as DNA 
copy number variations (CNV). When they occur in somatic cells, they are termed copy number 
alterations (CNA) [32]. Copy number changes may affect a large proportion of the human genome. 
In a study of 270 individuals, Redon et al. reported 1447 copy number variable regions covering 
360 megabases (12% of the genome) [33]. As discussed by Hastings et al., copy number changes 
are at least as important in determining the differences between individual humans as single 
nucleotide polymorphisms (SNPs), and appear to be a major driving force in evolution within the 
human and great ape lineage [30]. Copy number changes also have severe disadvantages. They are 
involved in many human diseases such as the Down syndrome caused by trisomy of human 
chromosome 21. Copy number changes caused by submicroscopic genomic deletions were found 
to be involved in human diseases such as thalassaemia and red-green color blindness [34]. Changes 
in copy number are also involved in cancer formation and progression [35]. 
The CNA data that we used in this thesis is TCGA level 3 data files. The process by which 
these files were generated contains three main steps. First, Affymetrix SNP 6.0 platform generates 
TCGA level 1 files, which contain original array intensity values. These files are then processed by 
Birdsuite [36]. Birdsuite first normalizes array intensity values. Then it estimates raw copy number 
and performs tangent normalization. In the third step, DNAcopy R-package [37] analyses the result 
files from Birdsuite (TCGA level 2 files) using circular binary segmentation algorithm and 
generates copy number segment files (TCGA level 3).  
2.1.3 Gene expression detected by microarrays  
DNA is the basic molecular unit of heredity; it carries the raw genetic information that can be turned 
into functional products, usually proteins [38]. Proteins are the main actors inside cells [39], they 
control the functions of the cell. Humans, for example, have over 200 different types of cells [40]. 
Cell identity is established by transcriptional regulation so that different sets of proteins are 
synthesized [41]. The expression of genes contains two main steps: transcription, where double–
stranded DNA is transcribed into single–stranded messenger RNA (mRNA) [42], and translation, 
when the mRNA molecule is translated into a protein [43]. Transcription proceeds in the following 
three phases [42]: 
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 Initiation: the enzyme RNA polymerase binds to a DNA molecule at the location of the 
promoter sequence (Figure 2.4-a). 
 Elongation: the double-strand DNA unwinds. RNA polymerase moves along template DNA 
strand and adds nucleotides to the three-prime (3’) end of RNA molecule (Figure 2.4-b). 
 Termination: transcription is completed when RNA polymerase meets the termination 
sequence on the DNA template strand. At this point, the mRNA transcript and RNA 
polymerase are released from the complex (Figure 2.4-c). 
 
Figure 2.4 Steps in transcription process. This image was taken from [42] 
During translation, the ribosome decodes the mRNA in blocks of three non-overlapping 
nucleotides, or codons, that each specifies an amino acid [44]. Table 2.1 lists all the possible codons 
and their corresponding amino acids. Translation proceeds in three phases [43]:  
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 Initiation: The two ribosome subunits bind to mRNA molecule. Normally, the first 
methionine-carrying tRNA is attached at the start codon (AUG). See Figure 2.5-A. 
 Elongation: The tRNA corresponding to the next codon transfer an amino acid to the 
ribosome. After a peptide bond is formed between amino acids, the ribosome moves to the 
next mRNA codon to continue the process. See Figure 2.5-B. 
 Termination: When the ribosome reaches a stop codon (UAA/UAG/UGA), it releases the 
polypeptide, and the translation is completed. 
 
 
Figure 2.5 Translation from mRNA to protein. This image was taken from [43] 
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Table 2.1 Genetic code. The genetic code is a three–letter code that defines the translation from three sequential nucleotides into 
an amino acid [45] 
  2nd base   
1st 
base 
U C A G 
3rd 
base 
U 
UUU 
Phenylalanine (Phe/F) 
UCU 
Serine (Ser/S) 
UAU 
Tyrosine (Tyr/Y)  
UGU 
Cysteine (Cys/C)  
U 
UUC UCC UAC UGC C 
UUA 
Leucine (Leu/L) 
UCA UAA Stop (Ochre) UGA Stop (Opal) A 
UUG UCG UAG Stop (Amber) UGG Tryptophan (Trp/W) G 
C 
CUU CCU 
Proline (Pro/P)  
CAU 
Histidine (His/H)  
CGU 
Arginine (Arg/R)  
U 
CUC CCC CAC CGC C 
CUA CCA CAA 
Glutamine (Gln/Q)  
CGA A 
CUG CCG CAG CGG G 
A 
AUU 
Isoleucine (Ile/I)  
ACU 
Threonine (Thr/T) 
AAU 
Asparagine (Asn/N)  
AGU 
Serine (Ser/S)  
U 
AUC ACC AAC AGC C 
AUA ACA AAA 
Lysine (Lys/K)  
AGA 
Arginine (Arg/R)  
A 
AUG Methionine(Met/M) ACG AAG AGG G 
G 
GUU 
Valine (Val/V) 
GCU 
Alanine (Ala/A)  
GAU 
Aspartic acid (Asp/D)  
GGU 
Glycine (Gly/G)  
U 
GUC GCC GAC GGC C 
GUA GCA GAA 
Glutamic acid (Glu/E)  
GGA A 
GUG GCG GAG GGG G 
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Proteins are the most functional macromolecules in living organisms, they play an important 
role in essentially all biological processes [46]. For this reason, measuring the expression of all 
genes in a cell is warranted. Nowadays, this is possible by various laboratory tests that identify all 
the genes in a cell or tissue that are making messenger RNA 
(https://www.cancer.gov/publications/dictionaries/cancer-terms/def/gene-expression-profile. 
Access date: September 10, 2018). One established technology for gene expression profiling are 
DNA microarrays. Microarrays consists of a large number of microscopic reaction volumes. Each 
volume contains a short segment of (mostly) linear DNA to which target cDNA labeled with a 
fluorescent tag can hybridize. The amount of fluorescence output is then of quantitative (gene 
expression) or qualitative (diagnostic) nature [47]. There are several microarray platforms including 
printed microarrays, in situ-synthesized oligonucleotide microarrays, high-density bead arrays, 
electronic microarrays, suspension bead arrays [47]. Besides being used to detect gene expression 
profiles, microarrays have been used in determining the binding sites of a transcription factor or as 
genotyping platforms to detect single nucleotide polymorphisms (SNP) [48]. Despite the fact that 
microarrays have been widely used, they still have limitations, e.g. a DNA array can only detect 
sequences that it was designed to detect. In case several genes have significant sequence homology, 
microarrays may detect all of them but they cannot distinguish these genes [48]. Recently, the 
microarray technique is being superseded by RNA-seq sequencing technologies [49]. 
2.1.4 Operon concept in prokaryotes 
As first mentioned by Monod and co-workers in 1960, an operon is a group of genes for which the 
expression is coordinated by a single promoter [50]. That paper characterized the lac operon in 
Escherichia coli [50], see Figure 2.6. The first element of this operon is a promoter, a nucleotide 
sequence that enables a gene to be transcribed. Transcription is initiated when this sequence is 
bound by RNA polymerase. The second element in the operon is termed operator. This is the place 
where the repressor (lacI regulator protein) can bind. The binding of the repressor to the operator 
stops transcription and makes the expression of genes fail. The third main element of the lac operon 
is a group of genes (lacZ, lacY, lacA). Because these genes are controlled by a single promoter [50], 
they are either expressed together or not at all. Osbourn and Field reported that genes in the same 
operon are usually related in function [51]. 
 
12 
 
 
Figure 2.6 Lac operon in E.coli. This image was taken from [52] 
 
2.1.5 Functional Annotation of Genes (Gene Ontology) 
The Gene Ontology (GO) was established by the Gene Ontology Consortium [53] by joining three 
databases: the Saccharomyces Genome Database [54], FlyBase [55], and Mouse Genome 
Informatics [56], [57]. This project was motivated by the observation that there exists large-scale 
functional conservation of genes in eukaryotic cells. In different eukaryotic genomes, many genes 
code for proteins having a role in “core biological processes” that are common to all eukaryotic 
cells, such as transcription, translation, DNA replication, and metabolism [53]. This conservation 
motivates the idea of automated transfer of biological annotations from well-studied organisms to 
other organisms [53]. To this end, GO provides a controlled vocabulary [53], [58] for the description 
of: 
 Cellular components – which refer to the place in the cell where a gene product is active.  
 Molecular functions – which are defined as the job or the “ability” of a gene product. 
 Biological processes – which refer to a specific objective that the gene or gene product aim 
to achieve. 
In principle, this vocabulary can be used to all eukaryotes regardless the accumulating and the 
changing of our knowledge about genes and roles of proteins in cells [53]. However, there are 
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certainly caveats since only a small fraction of these annotations is based on real, direct biological 
assays, whereas most annotations are “inferred based on electronic annotation” which is termed 
IEA in GO terminology [59]. 
Figure 2.7 shows an example of a GO term (data was retrieved from 
http://www.geneontology.org/ontology/obo_format_1_2/gene_ontology.1_2.obo. Access date: 
September 12, 2018) 
 
Figure 2.7 An example GO term 
The Gene Ontology consortium provides annotations through associations between GO terms and 
entries for genes or gene products. Annotation data files are available at 
http://www.geneontology.org/page/download-go-annotations. Another way to search and browse 
the GO database is provided by AmiGO 2 (http://amigo.geneontology.org/amigo/landing) [60]. 
2.1.6 Hallmarks of cancer 
In the year 2000, Hanahan et al. published a very influential review article on the “hallmarks of 
cancer” [61] where they organized the complexities of cancer biology into six major hallmarks: 
self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis. A decade later, an 
updating review [62] adjusted the six original hallmarks to sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis. The authors also added four new hallmarks: 
reprogramming energy metabolism, evading immune response, genome instability and mutation, 
and tumor-promoting inflammation. In 2014, Suzuki et al. assigned 2050 genes to the 10 cancer 
hallmarks [63] based on Gene Ontology annotations (Table 2.2).  
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Table 2.2 GO terms assigned to the hallmarks of cancer. This table was adapted from [63] 
Hallmark GO term id 
Activating Invasion and Metastasis GO:0045216, GO:0034329, GO:0045217, GO:0034334, 
GO:0016477, GO:0010718, GO:0007155 
Resisting Cell Death GO:0060548 ,GO:0012501, GO:0010941 
Evading Growth Suppressors GO:0007049, GO:0008283 
Avoiding Immune Destruction GO:0002507, GO:0001910, GO:0019882, GO:0002767 
Inducing Angiogenesis GO:0001525 
Deregulating Cellular Energetics GO:0006091 
Genome Instability and Mutation GO:0006281, GO:0051383, GO:0007062, GO:0000819, 
GO:0051988, GO:0030997, GO:0046605, GO:0060236, 
GO:0090169, GO:0043146, GO:0031577 
Tumor Promoting Inflammation GO:0006954, GO:0045321 
Enabling Replicative Immortality GO:0032202, GO:0000723, GO:0090398, GO:0090399 
Sustaining Proliferative Signaling GO:0007166, GO:0070848 
 
2.2 Proteins  
As mentioned in the previous section, proteins are products of gene expression. In the translation 
phase of a gene, multiple amino acids are linked together by peptide bonds to form a long chain 
called polypeptide [64]. A polypeptide can be folded into repeating structures called the alpha (α) 
helix, the beta (β) pleated sheet [65],the beta (β) turn [66], and omega (Ω) loop [67], [68]. The next 
level of complexity in polypeptide folding is the formation of tertiary structure. This is the complete 
three-dimensional structure of a protein [69]. Proteins have various functions. For example, they 
are the main component of antibodies like immunoglobulins [70], proteins termed enzymes can 
accelerate chemical reaction [71], proteins can be messengers (a hormone for example) when used 
to communicate between organs and tissues [72]. Proteins also provide support to protect and 
maintain cell shape [73]. In the following, we will introduce a specific class of proteins that work 
as membrane transporters. 
2.2.1 Transmembrane proteins 
Membrane proteins are associated with the membranes of a cell. In prokaryotes, these proteins play 
important roles in mediating the interaction between cell and surroundings [74]. Moreover, in 
eukaryotes, these proteins also catalyze transport processes into and out of intracellular 
compartments such as mitochondria or the endoplasmic reticulum [75], [76]. Figure 2.8 shows three 
ways how proteins can attach to the membrane. The Transporter Classification Database (TCDB) 
organizes transporter proteins into the following classes: channels/pores, electrochemical potential-
driven transporters, primary active transporters, group translocators, transmembrane electron 
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carriers, accessory factors involved in transport, and incompletely characterized transport systems 
[77]. 
 
Figure 2.8 Fluid mosaic model introduced by Singer–Nicholson. Image was taken form [78] 
 
2.2.2 Target proteins of antineoplastic drugs 
Cancer is a disease in which cells divide uncontrollably. Division of cells, in turn, depends on DNA 
replication, transcription, and translation. This makes DNA a major target for drug development 
against cancer [79]. Other important targets for anticancer drug development include RNA, 
enzymes, and other proteins [80]. Kumar et al. reviewed some anticancer drug mechanisms which 
are listed in Table 2.3 [79]. 
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Table 2.3 Anticancer drug mechanisms and their targets 
Antineoplastic mechanism Targets of antineoplastic agents 
Angiogenesis inhibitors Angiogenin, growth factor such as transforming 
growth factor-β (TGF-β), vascular endothelial 
growth factor (VEGF), and fibroblast growth factor 
(FGF). 
DNA Intercalators and Groove Binding Agents Proteins associated with recognition and function of 
DNA (e.g. transcription factors, polymerases, DNA 
repair systems, and topoisomerases). 
DNA Synthesis Inhibitors Folic acid plays an important role in de novo 
synthesis of purines, thymidylate, and polyamines. 
This in turn affects de novo synthesis of DNA in 
mammalian cells. 
Transcription Regulators Transcription factors. 
Enzyme Inhibitors Metabolic enzymes (e.g. pyruvate kinase M2, 
glucose transporters, hexokinase, fatty acid 
synthase, lactate dehydrogenase A, and pyruvate 
dehydrogenase kinase) when inhibited may induce 
apoptotic death in cancer cells. 
Gene Regulation Histone deacetylases are responsible for the 
deacetylation of histones in cells. This is important 
for transcriptional regulation.  
Microtubule Inhibitors Microtubules, components of the cytoskeleton, are 
involved in many biological processes such as cell 
intracellular transport, cytokinesis, signaling, 
maintenance of cell shape, and polarity. 
 
2.3 Pathways 
The KEGG pathway map is a network diagram of molecular interaction/reaction. This map is 
represented in terms of the KEGG Orthology (KO) groups. This allows the experimental evidence 
in specific organisms can be transferred to other organisms [81]. Each map contains graphics 
objects that are linked to KEGG objects. Basic graphics objects in the reference KEGG pathway 
maps are: 
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 boxes - ortholog (KO) groups identified by K numbers (KO identifiers). In metabolic maps, 
boxes represent reactions that are identified by R numbers.  
 circles - other molecules identified by C numbers. They are usually chemical compounds. 
 lines - reactions identified by R numbers in metabolic maps. In global metabolism maps, 
lines represent ortholog (KO) groups. 
While reference KEGG pathway maps are drawn manually, organism specific pathway maps are 
computationally generated. In the latter ones, boxes contain genes or gene products. Each pathway 
map has an identifier made up by the combination of a 2-4 letter code and a 5-digit number (e.g. 
hsa01521). The prefix letter code can be one of the following: 
 ko - Reference pathway (KO)  
 map - Reference pathway 
 rn - Reference pathway (Reaction) 
 ec - Reference pathway (EC)  
 org - Organism-specific pathway map (this prefix for Homo sapiens is hsa, for Escherichia 
coli K-12 MG1655 is eco …the full list of organisms is available at 
https://www.genome.jp/kegg/catalog/org_list.html) 
A collection of pathway maps are stored in the KEGG PATHWAY database and represent 
knowledge on the molecular interactions, reactions and relation networks for metabolism, cellular 
processes, environmental information processing, genetic information processing, human diseases, 
organismal systems, and drug development [82]. 
2.3.1 Antineoplastic resistance pathways 
KEGG PATHWAY contains four pathway maps showing mechanisms of resistance for four 
categories of anticancer drugs including epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor, platinum, antifolate, and endocrine.  
EGFR tyrosine kinase inhibitor resistance (hsa01521) - Most outstanding resistant 
mechanisms to EGFR tyrosine kinase inhibitor treatment are “the secondary EGFR mutation 
(T790M), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), activation of 
alternative pathways (c-Met, HGF, AXL), histologic transformation, and impairment of the EGFR-
TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism)” [83].  
Endocrine resistance (hsa01522) - Cells may develop resistance to an endocrine drug by 
“loss of ER-alpha expression, ligand-independent growth factor signaling cascades that activate 
18 
 
kinases and ER-phosphorylation, altered expression of coactivators or coregulators that play a 
critical role in ER-mediated gene transcription, deregulation of the cell cycle and apoptotic 
machinery, and altered availability of active tamoxifen metabolites regulated by drug-metabolizing 
enzymes, such as CYP2D6” [84]. 
Antifolate resistance (hsa01523) - Mechanisms of antifolate resistance include “augmented 
drug export, virtue of impaired drug transport into cells, impaired activation of antifolates through 
polyglutamylation, increased expression and mutation of target enzymes, augmented hydrolysis of 
antifolate polyglutamates, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells” 
[85]. 
Platinum drug resistance (hsa01524) - Platinum-based drugs cause cellular apoptosis  by 
binding to purine DNA bases. Therefore, platinum can be resisted by “decreased binding of the 
drug to target (e.g., due to high intracellular pH), decreased mismatch repair, increased DNA repair, 
defective apoptosis, and altered oncogene expression”. Other mechanisms are “increased drug 
efflux, decreased drug influx, intracellular detoxification by glutathione, etc.” [86] 
2.4 Machine learning 
In the year 1959, the term machine learning was introduced by Arthur Samuel in an article published 
in the IBM Journal of Research and Development [87]. Machine learning refers to the ability of 
computer systems to solve problems without being explicitly programmed [88]. In the field of 
machine learning, researchers aim to study and construct algorithms for building a model. After 
learning from input data, the result model that can be used to make predictions on new coming data 
[89]. Broadly speaking, there are two main approaches for machine learning algorithms: supervised 
and unsupervised learning. The former starts with the goal of predicting a known output or target 
[90]. In contrast, in unsupervised learning, there are no outputs to predict. Instead, learning 
algorithms try to find naturally occurring patterns or groupings within the data [90]. Examples of 
supervised learning algorithms include linear regression, naive Bayes classifier, and support vector 
machines. In contrast, unsupervised learning algorithms include diverse clustering methods such as 
hierarchical clustering and k-means clustering. 
2.4.1 Support Vector Machines 
A support vector machine (SVM) [91] is a supervised learning model which is used for data 
classification and regression analysis. Like the other methods, we need to train our model first based 
on a suitable training set of “positive” and “negative” data points. SVM training constructs a 
hyperplane in order to separate training data belonging to these two classes (Figure 2.9).  
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Figure 2.9 An example SVM in 2 dimensional space. Image was adapted from [91] 
 
Let n points in training data be 
(𝑥1⃗⃗  ⃗, 𝑦1), … , (𝑥𝑛⃗⃗⃗⃗ , 𝑦𝑛) 
where  𝑦𝑖 indicate the class to which the point 𝑥𝑖⃗⃗  ⃗ belongs. Values of 𝑦𝑖 are either -1 or 1. Each 𝑥𝑖⃗⃗  ⃗ is 
a p-dimensional vector. Our goal here is to find the "optimal hyperplane" that divides the group of 
points 𝑥𝑖⃗⃗  ⃗  for which 𝑦𝑖=1 from the group of points for which 𝑦𝑖=-1, so that the distance between the 
hyperplane and the nearest point 𝑥𝑖⃗⃗  ⃗  from either group is maximized (optimal margin). 
If the training data is linearly separable, the classification function f is a linear function: 
𝑓(𝑥 ) = 𝑤𝑇𝑥 + 𝑏 
where w and b are the parameters of the classifier. The class of 𝑥  is the sign of the function 𝑓(𝑥 ). 
The hyperplane can be written as the set of point 𝑥  satisfying 
𝑓(𝑥 ) = 𝑤𝑇𝑥 + 𝑏 = 0 
and the two margins as follow: 
𝑤𝑇𝑥 + 𝑏 = 1     
𝑤𝑇𝑥 + 𝑏 = −1 
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For every data point, we have 𝑦𝑖(𝜔
𝑇𝑥𝑖⃗⃗  ⃗ + 𝑏) ≥ 1. 
If the data is not linearly separable, we may allow misclassification. By adding a cost ε𝑖 > 0, the 
optimization constraints become 
𝑦𝑖(𝜔
𝑇𝑥𝑖⃗⃗  ⃗ + 𝑏) ≥ 1 − 𝜀𝑖 
If 0 < ε𝑖 < 1, the point 𝑥𝑖⃗⃗  ⃗  is correctly classified but within the margin. If ε𝑖 > 1, the point is in the 
hyperplane or on the wrong side of it. We want to maximize the margin and minimize the cost. 
Another approach is using non-linear classifiers by transforming data into higher-dimensional 
space. This transformation is achieved using kernel functions. Examples of kernel functions include 
polynomial, hyperbolic tangent, and Gaussian radial basis functions. 
So far, our SVM model only works with two classes (binary classifier). An approach for classifying 
with more than two classes is reducing the single multiclass problem into multiple binary 
classification problems [92]. Common methods for such reduction include: one-against-all [93], 
one-against-one [94], and directed acyclic graph SVM [95]. 
2.4.2 Model validation and evaluation 
It is often useful to measure the performance of the model so that we can choose an appropriate 
method for a specific problem or tune the parameters of the model to improve the results. There are 
many metrics that can be used to measure the performance of a classifier. Performance measures 
are usually based on:  
 Success: the class label of data point is predicted correctly 
 Error: : the class label of data point is predicted incorrectly 
Examples of performance metrics include: 
 Error rate: proportion of incorrectly classified instances over the whole set of instances 
 Accuracy: proportion of correctly classified instances over the whole set of instances 
In the field of machine learning, to visualize the performance of an algorithm, people usually uses 
a specific table called confusion matrix (Table 2.4). 
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Table 2.4 Confusion matrix 
 Predicted condition positive Predicted condition negative 
True condition positive True positive (TP) False negative (FN) 
True condition negative False positive (FP) True negative (TN) 
 
The following metrics can be derived from Table 2.4 : 
 Accuracy (ACC) = 
TP+TN
TP+TN+FP+FN
 
 Prevalence = 
TP+FN
TP+TN+FP+FN
 
 Positive predictive value (PPV), Precision = 
TP
TP+FP
 
 False discovery rate (FDR) =  
FP
TP+FP
 
 False omission rate (FOR) = 
FN
TN+FN
 
 Negative predictive value (NPV) = 
TN
TN+FN
 
 True positive rate (TPR), Recall, Sensitivity, probability of detection = 
TP
TP+FN
 
 False positive rate (FPR), Fall-out, probability of false alarm = 
FP
FP+TN
 
 Specificity (SPC), Selectivity, True negative rate (TNR) = 
TN
FP+TN
 
 False negative rate (FNR), Miss rate = 
FN
TP+FN
 
 Positive likelihood ratio (LR+) = 
TPR
FPR
 
 Negative likelihood ratio (LR−) = 
FNR
TNR
 
 Diagnostic odds ratio (DOR) = 
LR+
LR−
 
 F1 score = 
2TP
2TP+FP+FN
 
In the following, three methods to estimate classifier problems will be explained. The first 
one is the holdout method. This method separates data into two sets, one for training (training set) 
and the other for testing (test set). One disadvantage of this method is that fewer labeled examples 
are available for training (because the test set holds some examples). Consequently, the result model 
may not be as good as when all the labeled examples are used for training [96]. The second method 
is cross-validation. In this method, data is segmented into k equally-sized partitions. Each iteration 
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uses one of the partitions for testing and the other remaining partitions for training. To use each 
partition for testing exactly once, this procedure is repeated k times. A special case of cross 
validation occurs when k is equal to the size of the data set so that each test set only contains one 
record. This case is called leave-one-out cross validation. The third method is bootstrap. Not like 
holdout or cross-validation, in which training records are sampled without replacement, in the 
bootstrap, a record already chosen for training is put back into the original pool of records. 
2.5 Statistical hypothesis tests 
“A statistical hypothesis is an assertion or conjecture concerning one or more populations” [97]. 
Here are some examples of statistical hypotheses: 
 The mean age of cats is 10 years. 
 The variable Hm, representing the height of male students, is approximately normally 
distributed. 
 The new drug is better than penicillin. 
Unless we examine the whole population, the falsity or truth of a statistical hypothesis is 
never known with absolute certainty. Because examining the entire population would be impossible 
in most real-life situations, we take a random sample from the population and use it to provide 
evidence that either supports or does not support the hypothesis. The hypothesis will be rejected if 
it is not consistent with the evidence from the selected sample. The process that leads to the decision 
of accepting or rejecting a statistical hypothesis is called statistical hypothesis testing. 
In hypothesis testing, the term null hypothesis (denoted by H0) refers to any hypothesis we 
want to test. We need an alternative hypothesis (H1) in case H0 is rejected. The alternative 
hypothesis is often the logical complement to null hypothesis. The three examples above now 
become: 
 {
𝐻0: The mean age of cats is 10 years                         
𝐻1: The mean age of cats is greater than 10 years
 
 {
𝐻0: The variable 𝐻𝑚, representing heights of male students, is approximately normally distributed                     
𝐻1: The variable 𝐻𝑚, representing heights of male students, is not normally distributed                                         
 
 {
𝐻0: The new drug is the same as penicillin
𝐻1: The new drug is better than penicillin 
 
2.5.1 Shapiro–Wilk test of normality 
The Shapiro–Wilk test, published in 1965 by Samuel Sanford Shapiro and Martin Wilk [98], is a 
way to tell if a random sample comes from a normal distribution. The statistic is 
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𝑊 =
(∑ 𝑎𝑖𝑥(𝑖)
𝑛
𝑖=1
)
2
∑ (𝑥𝑖−?̅?)
2𝑛
?̇?=1
, 
where  
 𝑥(𝑖) is the ith-smallest number in the sample; 
 ?̅? =
𝑥1+⋯+𝑥𝑛
𝑛
 is the sample mean; 
 the constants ai are given by 
o (𝑎1, … , 𝑎𝑛) =
𝑚𝑇𝑉−1
(𝑚𝑇𝑉−1𝑉−1𝑚)
1
2⁄
 
o where 𝑚 = (𝑚1, … ,𝑚2)
𝑇 
o and 𝑚1, … ,𝑚2 are the expected values of the standard normal order statistic. 
o V is the covariance matrix of standard normal order statistics. 
The percentage point of W test is then computed or looked up in the table published by 
Shapiro and Wilk [98]. If the value is greater than the chosen alpha level, we do not have evidence 
to reject the null hypothesis, which means the data came from a normally distributed population. 
On the other hand, if this value is less than the chosen alpha level, then we have evidence that the 
data tested are not normally distributed, and the null hypothesis is rejected.  
2.5.2 T-test  
In the year 1908, William Sealy Gosset introduced the t-test in the journal Biometrika under his pen 
name Student [99]. The are two common types of t-tests, one-sample t-test and two-sample t-test, 
with one of the most important assumption that the underlying distribution which samples were 
taken from are normally distributed [100]. 
The aim of a one-sample t-test is to compare the population’s mean with a specified value 
μ0. The t statistic can be calculated as follow 
𝑡 =
?̅? − 𝜇0
𝑠
√𝑛
 
Where n is the sample size, ?̅? is sample mean, and s is the standard deviation of the sample. The 
degree of freedom used in this test is n-1. 
The aim of a two-sample t-test is to compare the means of two populations. If the two 
samples have the same variance, the t statistic can be calculated as  
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𝑡 =
?̅?1 − ?̅?2
𝑠𝑝 . √
1
𝑛1
+
1
𝑛2
 
where ?̅?𝑖 is the sample mean from a sample X1, X2, and 𝑠𝑝 = √
(𝑛1−1)𝑠𝑋1
2 +(𝑛2−1)𝑠𝑋2
2
𝑛1+𝑛2−2
 
In two-sample t-test, the degrees of freedom for each group is ni – 1,  and the total number 
of degrees of freedom is n1 + n2 − 2. 
If the two samples have unequal variances, Welch's t-test (an adaptation of Student's t-test) 
is applied [101]. The t statistic can be calculated as  
𝑡 =
?̅?1 − ?̅?2
𝑠?̅?
 
where ?̅?𝑖 is the sample mean from a sample X1, X2, and 𝑠?̅? = √
𝑠1
2
𝑛1
+
𝑠2
2
𝑛
 
Here si
2 is the unbiased estimator of the variance of sample i, ni is the size of sample i (1 or 
2). The degrees of freedom are calculated using 
𝑑. 𝑓. =
(
𝑠1
2
𝑛1
+
𝑠2
2
𝑛2
)
2
(
𝑠1
2
𝑛1
⁄ )
2
𝑛1 − 1
+
(
𝑠2
2
𝑛2
⁄ )
2
𝑛2 − 1
 
After having evaluated the t statistic, we can compute p-value as explained in [100]. The 
null hypothesis will be rejected if the p-value is less than a given small alpha value. 
2.5.3 Wilcoxon rank-sum test 
In statistics, the Wilcoxon rank-sum test (also called Mann–Whitney U test) [102], [103] is a 
nonparametric test that allows two populations to be compared without making the assumption that 
the values are normally distributed. For this reason, the Wilcoxon rank-sum test is an alternative to 
the t-test. The test requires the calculation of a U statistic as follows 
1. Merge two samples into one set, and sort this set in ascending order. 
2. For each and every observation, assign a numeric rank starting with 1. We assign the same 
rank, which is the midpoint of unadjusted rankings, for the observations that have equal 
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values. E.g., the ranks of (2, 4, 4, 4, 9) are (1, 3, 3, 3, 5) (the unadjusted rank would be (1, 
2, 3, 4, 5)). The sum of all the ranks is N(N+1)/2 where N is the total number of observations. 
3. Sum up the ranks of the observations which belong to sample 1. U is then given by [104] 
𝑈 = 𝑛1𝑛2 +
𝑛1(𝑛1 + 1)
2
− 𝑅1 
where n1 and n2 are the number of observation in sample 1 and 2, respectively, and R1 is the 
sum of the ranks in sample 1. The U statistic can also be calculated as 
𝑈′ = 𝑛2𝑛1 +
𝑛2(𝑛2 + 1)
2
− 𝑅2 
where R2 is the sum of the ranks of the observations in sample 2.  
The calculated 𝑈 or 𝑈′ – whichever is larger – is compared with the two-tailed value of 𝑈𝛼(2),𝑛1,𝑛2of 
the Wilcoxon rank–sum distribution. If one of the calculated U values is greater than or equal 
to 𝑈𝛼(2),𝑛1,𝑛2 then the null hypothesis is rejected, which means that the two populations’ 
distributions are not the same. 
2.5.4 Fisher's exact test 
Fisher's exact test is a statistical test used to analyze the associations between two categorical 
(classification) variables [105]. The null hypothesis for the test is that there is no association 
between two categorical variables. Ronald Fisher said the test was motivated by Muriel Bristol, 
when she claimed her ability of detecting whether the milk or the tea was added first to her cup 
[106]. Table 2.5 shows an example result of the “lady testing tea” experiment. 
Table 2.5 Result of “lady testing tea” experiment 
 Actual number of cups 
where milk was added first 
Actual number of cups 
where tea was added first 
Row total 
Predicted number of cups 
where milk was added first 
a b R1 = a + b 
Predicted number of cups 
where tea was added first 
c d R2 = c + d 
Column total C1 = a + c C2 =b + d a + b + c + d 
(=n) 
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According to Fisher, the probability of obtaining any such set of values follows the 
hypergeometric distribution and can be computed as 
𝑝 =
(
𝑎 + 𝑏
𝑎
) (
𝑐 + 𝑑
𝑐
)
(
𝑛
𝑎 + 𝑐
)
=
(𝑎 + 𝑏)! (𝑐 + 𝑑)! (𝑎 + 𝑐)! (𝑑 + 𝑏)!
𝑎! 𝑏! 𝑐! 𝑑! 𝑛!
 
where (
𝑛
𝑘
) is the binomial coefficient and the symbol “!” indicates the factorial operator. 
Next, we find all possible matrices that have nonnegative integers consistent with the row 
and column sums Ri and Cj. Then we calculate the associated conditional probability for each 
matrix. To compute the p-value of the test, probabilities of the tables (matrices) that represent equal 
or greater deviation than the observed table are added together [107].  
2.5.5 False discovery rate 
When conducting statistical hypothesis tests, for example a t-test with null hypothesis that two 
populations have the same means, we calculate the p-value. If we had a p-value less than a chosen 
significant level alpha, for example p-value = 0.0234 and alpha = 0.05, we reject the null hypothesis 
and say that the means are significantly different. If the null hypothesis is actually true and we reject 
it, then we make a mistake. This mistake is called type I error, or a false positive. We usually like 
to keep this probability of a type I error small (under 5% for example).  
When conducting multiple comparisons, the probability that at least one of the tests is 
rejected when it is actually true is computed as follow: 
𝑝 = 1 − (1 − 𝛼)𝑚 
where m is the number of comparisons, and 𝛼 is significant level. If m = 10 and 𝛼 = 0.05, the 
probability that at least one of the tests get the type I error is about 40%. If m = 1000 and 𝛼 = 0.05, 
there are (on average) 50 tests that were falsely rejected based on the null hypothesis. Table 2.6 
defines the possible outcomes when testing multiple null hypotheses. The number of hypotheses m 
is known, R is observable variable, while U, V, S, and T are unobservable variables. 
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Table 2.6 Number of errors committed when testing m null hypotheses. Table is adapted from 
[108] 
  
Null hypothesis is 
true (H0) 
Alternative hypothesis 
is true (HA) 
Total 
Test is declared significant (H0 
is rejected) 
V S R 
Test is declared non-significant 
(H0 is not rejected) 
U T m-R 
Total m0 m-m0 m 
 
When we falsely reject null hypotheses, the proportion of errors can be computed by the 
random variable Q = V/(V + S). Q is defined to be zero when R = V + S = 0. Because V and S are 
unobservable variable, Q is also an unobservable variable. False discovery rate (FDR) is defined to 
be the expectation of Q [108], 
FDR = E(Q) = E{V/(V+S)} = E(V/R) 
FDR-controlling procedures are designed in respond the need that we want to identify as many 
significant (reject null hypothesis) tests as possible while keeping a relatively low proportion of 
false positives (falsely rejecting null hypotheses). In the following, the Benjamini–Hochberg 
procedure [108] and the Benjamini–Hochberg–Yekutieli [109] procedure will be explained. 
Benjamini–Hochberg procedure: 
 Sort all p-values in ascending order.  
 Assign ranks to the p-values, starting from 1.  
 Calculate Benjamini-Hochberg critical value for each individual p-value , using the formula 
𝑃𝐵−𝐻 =
𝑖
𝑚
𝑄,  
where i is the rank of individual p-value, m is the total number of tests, and Q is the false 
discovery rate (a percentage, chosen by user).  
 Compare original p-value to the corresponding critical PB-H; tests have original p-value 
smaller than the critical value are significant.  
Benjamini–Hochberg–Yekutieli procedure controls the FDR under positive dependence 
assumptions [109]. This procedure is similar the one just described except that the critical value is 
computed as 
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 𝑃𝐵−𝐻−𝑌 =
𝑖
𝑚.𝑐(𝑚)
𝑄,  
 If the tests are positively correlated or independent then c(m)=1. 
 Under arbitrary dependence 𝑐(𝑚) = ∑
1
𝑖
𝑚
𝑖=1
 
 If the tests are negative correlated, we can approximately compute c(m) by using the Euler–
Mascheroni constant 𝛾 [110] as follow: 
𝑐(𝑚) = ∑
1
𝑖
𝑚
𝑖=1
≈ 𝑙𝑛(𝑚) + 𝛾 +
1
2𝑚
  
2.6 External tools used 
2.6.1 GISTIC 2.0: Identifying genes recurrently affected by CNAs 
Genomic Identification of Significant Targets in Cancer (GISTIC) is a method designed for 
analyzing somatic copy-number alterations (SCNA) in cancers [111]. GISTIC identifies those 
regions of the genome that are aberrant more often than would be expected by chance. These regions 
contain “driver” genes that affect the initiation or progress of tumors. In the year 2011, four years 
after GISTIC was introduced, Beroukhim et al. released GISTIC2.0 [112]. The new version can 
model complex cancer genomes that contain a mixture of SCNA types occurring at distinct 
background rates. GISTIC2.0 also provides a priori statistical confidence in interpreting copy-
number analyses. Figure 2.10 shows the main steps of both versions of GISTIC. 
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Figure 2.10 Schematic overview of GISTIC1.0 and GISTIC2.0. Image was taken from [112] 
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Chapter 3 Annotating the function of protein-coding genes based on 
Gene Ontology terms of neighboring co-expressed genes 
 
This chapter is based on the following publication: 
 Tran, V.H., Barghash, A., Helms, V. Annotating the function of protein-coding genes based on 
Gene Ontology terms of neighboring co-expressed genes. (2018) Journal of Proteomics & 
Bioinformatics, V. 11, p. 868-874, doi: 10.4172/jpb.1000468.  
My contribution was to design the research project and analyze the results together with the co-
authors Ahmad Barghash and Volkhard Helms. I and Volkhard Helms prepared the manuscript. I 
collected data, implemented the machine-learning classifier and performed the calculations. 
3.1 Introduction  
In times of high-throughput sequencing and transcriptomics, the amount of sequencing data is 
quickly piling up. Yet, may proteins have still not been annotated with their cellular functions due 
to experimental difficulties (time-consuming and costly) involved with functional assays [113]. To 
address this problem, many computational methods were developed to predict the functions of 
proteins. The earliest methods were based on the sequence homology between proteins or on 
sequence motifs of proteins (e.g. PRINT-S [114], BLOCK [115], PROSITE [116], InterPro [117], 
transportDB [118]). As proteins exist and work as three-dimensional structures, protein structures 
are also a valuable indicator of similar functions between proteins [119]. Other prediction methods 
consider the genomic context [120]–[122] or their neighborhood in protein-protein interaction 
networks [123]–[125]. Recently, also some tools using natural language processing have been 
presented (e.g. GOstruct [126], Text-KNN [127] and PPFBM [128]).  
  An important yet neglected field is that of membrane proteins. According to Krogh et al. 
[9], about 21% of the Escherichia coli genes encode transmembrane proteins. The corresponding 
numbers are 21% in Saccharomyces cerevisiae, 30% in Caenorhabditis elegans and 20% in 
Arabidopsis thaliana. Transmembrane proteins play important roles, especially in mediating the 
interaction between cells and their surroundings. Thus, membrane proteins are important targets for 
drugs (about 60% of all modern medical drugs [16]). Of particular interest for the prediction of 
protein function is the subgroup of membrane transporters because they comprise the second largest 
protein family in Homo sapiens, next to G-protein coupled receptors. However, it is experimentally 
hard to identify their substrate specificities [10].  
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Previously, substrate specificities of membrane transporters have been predicted, for 
example, based on sequence homology [11] and amino acid composition [12]–[14]. Meta-methods 
that combine different features for functional annotation often gave improved performance 
compared to single-feature methods. For example, Yayun Hu et al. used four sequence features 
including amino acid composition, composition, transition and distribution properties, position-
specific scoring matrices, and biochemical properties to annotate the substrate specificity of ABC 
transporters [15]. They reported an accuracy of 88% to distinguish between four classes of ABC 
transporters. Still, it is worthwhile to characterize the benefits of individual features before 
combining them with others. 
In this study, we combined genomic context-based methods with Gene Ontology (GO 
annotations) [53] and gene expression data. One motivation behind considering the co-location and 
co-expression of neighboring genes is the principle of operons in bacterial genomes. Genes in an 
operon are controlled as a single unit by a single promoter [129] and thus are either expressed 
together or not at all. They are usually related in function too [51]. Also genes in eukaryotic 
genomes have been reported to have a tendency to cluster when showing similar expression, and 
the genes in these clusters tend to have related functions [130]–[135]. Wang and colleagues, as well 
as Barkai and colleagues showed that if two eukaryotic genes have the same expression levels in 
different conditions, they are likely to be members of the same protein complex or to participate in 
the same biological pathways [136], [137]. Also, Lee and Sonnhammer reported that genes involved 
in the same biochemical pathways tend to gather in various eukaryotic genomes [132]. These 
relationships between gene co-expression, neighborhood and functions have been frequently 
exploited in functional genomics studies, e.g. to predict protein interaction partners [138], [139], to 
identify and analyze gene position clusters [140] and by the STRING database [141]. A quasi-
standard for functional annotation is the controlled vocabulary compiled by the Gene Ontology 
Consortium [53]. The Gene Ontology (GO) annotations  can be used in functional profiling, 
functional categorizing and to predict gene function [142]. Here we combined these techniques and 
tested how well this method works in prokaryotes and eukaryotes. 
To predict the functions of a protein, we first retrieve the neighboring genes of the respective 
protein-coding gene and then compute the co-expression correlation between this central gene and 
its neighbors. The GO term lists of the central gene and of the neighboring genes that exhibit the 
highest correlation to the central gene are used to create input data for a support vector machine 
(SVM) classifier. SVM models are then used for classifying the function of so far uncharacterized 
genes. 
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3.2 Material and methods 
3.2.1 Dataset 
For training and testing of the classifiers, we selected the well-studied model organisms Escherichia 
coli and Saccharomyces cerevisiae for which high confidence datasets are available. Later we used 
a Homo sapiens dataset to test the method. For each organism, transporter proteins and metabolic 
enzymes were selected. These proteins are called central proteins (and the genes encoding these are 
called central genes thereafter) to distinguish them from their neighboring genes. 
3.2.1.1 Transporter proteins 
From the Transporter Classification Database (TCDB) [143] we retrieved two sets of membrane 
transporters that facilitate the transport of either amino acids or sugar molecules across the 
membrane. Table 3.1 lists the number of proteins for the three organisms. 
Table 3.1 Number of transporters belonging to different groups and organisms according to 
TCDB 
  Organism 
  
Escherichia coli 
Saccharomyces 
cerevisiae 
Homo sapiens 
G
ro
u
p
 Amino Acid Transporters 47 24 37 
Sugar Transporters 39 17 13 
 
3.2.1.2 Enzymes in metabolic pathways 
Beside transporter proteins, we also used enzymes of metabolic pathways in Escherichia coli to test 
our method. Four groups of metabolic pathways involved in carbohydrate, lipid, amino acid, and 
nucleotide metabolisms were collected. The lists of enzymes for each group were downloaded from 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway maps, under the tag 
“metabolism” and the four respective sub-tags, e.g. carbohydrate metabolism, lipid metabolism, 
nucleotide metabolism, and amino acid metabolism [144]. The gene identifiers of the four groups 
are listed in Supplement table 1. The groups contain 187 genes (amino acid metabolism), 253 
(carbohydrate metabolism), 45 (lipid metabolism), and 99 genes (nucleotide metabolism), 
respectively. 
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3.2.1.3 Data used for functional annotation 
Neighboring genes: From the BioCyc database, we downloaded information about all genes 
of Escherichia coli, Saccharomyces cerevisiae, and Homo sapiens [145], [146]. We then rearranged 
the list of genes according to increasing genomic positions. Sorting these files helps in finding 
neighboring genes more easily. We use the term neighboring genes for genes on the same 
chromosome that have close genomic positions. 
GO terms: We retrieved tab-delimited files with gene symbols and GO terms from the Gene 
Ontology Consortium [53].  
Microarrays data: We used Pearson correlation to measure the co-expression of genes. For 
Escherichia coli we used preprocessed and normalized microarray expression data from Dataset 
Record GSE1121 [147] whereas for Saccharomyces cerevisiae we used respective data from 
Dataset Record GDS91 [148]. For Homo sapiens, we used data for colon adenocarcinoma patients 
from TCGA, but only selected data files from normal samples. After finding neighboring genes, the 
co-expression correlation between a gene and its neighbors was computed as:   
𝜌 =
∑ (𝑥𝑖 − ?̅?)
𝑛
𝑖=1 (𝑦𝑖 − ?̅?)
√∑ (𝑥𝑖 − ?̅?)2
𝑛
𝑖=1 √∑ (𝑦𝑖 − ?̅?)
2𝑛
𝑖=1
 
where: 
xi is expression value of gene x in ith sample 
yi is expression value of gene y in ith sample 
n is the number of samples 
?̅? =
1
𝑛
∑ 𝑥𝑖
𝑛
𝑖=1 ; and analogously for ?̅? 
3.2.2 Methods 
Figure 3.1 shows the basic steps in this project. To retrieve the neighboring genes, we look for them 
both upstream and downstream of the current gene. The number of neighbors upstream, is denoted 
as n, is equal to the number of neighbors downstream. The number of selected neighbors that 
possess highest co-expression correlation with current gene is denotes as N. A pair of number of 
neighbors and number of selected neighbors are written as (n, N) which we refer to as window size. 
In the result section, we show the results for three different window sizes (5, 3), (10, 3), and (20, 
5). 
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Figure 3.1 The workflow of basic steps in this project 
 
3.2.2.1 Training and testing data for SVM 
The dataset of each organism was split into two subsets, the training set and the test set. In this 
project, we used one record for testing and all other records for training. Then for each protein group 
in the training set, we created two lists. One list contains the selected genes and the other list 
contains all the neighbors of the selected (central) genes. After that, we retrieved the GO terms for 
every gene in these lists. From then on, we only worked with these lists of GO terms. For example, 
if we have two groups of transporter proteins (amino acid transporters and sugar transporters), then 
we have four lists of GO terms (the first list contains all GO terms of all amino acid transporters in 
the training set, the second list contains all GO terms of all neighboring genes of these amino acid 
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transporters, the third list contains all GO terms of all sugar transporters in the training set, and the 
fourth list contains all GO terms of all neighboring genes of sugar transporters). 
For each central gene in the training set, we selected maximum N neighbors that have the 
highest co-expression correlation with the central gene. Then we identified the GO terms for each 
selected neighbor. After that, we computed the percentage of GO terms that are contained in each 
GO list. If this percentage was greater than or equal to a pre-selected threshold (r) then we assigned 
the value 1, otherwise we assigned the value 0. As a test, we also used real-valued functional 
similarities obtained from GOSemSim [149]. Yet, this strategy gave results of lower quality than 
the binary-valued approach. Using binary-value has a disadvantage, because a higher threshold (r) 
yields more 0 values. For some cases we did not obtain a value of 1 at all, and a vector with all 0 
values is not usable for SVM. Supplement table 2, Supplement table 3 and Supplement table 4 
summarize the number of genes that we found suitable to use to build the models. For gene ArtQ  
of Escherichia coli (see Figure 3.2) in the training set, for example, we selected the neighbors that 
had the highest co-expression levels (ArtM, ArtI and ArtP). If neighbor ArtI is selected, we compute 
what percentage of its GO terms are contained in each of the four lists of GO terms. If this 
percentage is greater than or equal to a pre-selected threshold (r) then we assigned the value 1, 
otherwise we assigned the value 0. Since we have four GO term lists, this gives four values. If we 
select three neighbors that have the highest co-expression correlation then we have 3x4=12 values 
of 0 or 1. We used these twelve features together with the group’s names, that were converted to 
positive integer values, as class label to train the classifier. These steps were repeated for all genes 
in the testing set. 
3.2.2.2 Support vector machine for classification 
Support Vector Machine classification [91] of substrate specificity or of participation in metabolic 
pathways was done with the software LIBSVM [150]. LIBSVM can efficiently classify samples 
into multiple classes, it automatically selects a model, which can generate contours of the cross 
validation accuracy, and it makes cross-validation for model selection and treats unbalanced data 
by using a weighted SVM. In this project, we used leave-one-out cross validation. LIBSVM also 
provides various kernel functions and different SVM formulations. We tested our method with three 
kernel functions (linear, radial basis function (RBF), and sigmoid). In most cases with different 
threshold r, number of neighboring genes or organisms, RBF gave the best results. Then we 
proceeded using RBF and tested for different values of the cost parameter (0.1, 0.5, 1. 1.5, 5 and 
10). The default cost parameter of 1 gave the best results. A lower value of 0.1 gave the worst 
accuracies. The reliability increases substantially when cost changes from 0.1 to 0.5. The accuracies 
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of Saccharomyces cerevisiae changed by 15%, accuracies of Escherichia coli by 5.6 % and of 
Homo sapiens by 11.6% at most, respectively. With cost parameter greater than or equal to one, the 
accuracies did not show remarkable changes. We also tested four different values of the gamma 
parameter (1.0, 0.8, 0.5, 0.3 and default value of gamma). The default value of gamma gave better 
accuracies than other values in most of the cases. For this reason, we kept the default values of all 
the parameters. 
3.2.2.3 Model validation and evaluation 
We used leave-one-out cross validation to evaluate the prediction ability of our model. In the leave-
one-out cross validation, one record was used for testing, all others were used for training. The 
process of training and testing was repeated until all records had been used for testing once. 
Accuracy (ACC) was evaluated in the usual way as: 
𝐴𝐶𝐶 =  
𝑇𝑃 + 𝑇𝑁
𝑇𝑃 + 𝐹𝑃 + 𝑇𝑁 + 𝐹𝑁
 
where TP, FP, TN and FN are true positive, false positive, true negative, and false negative, 
respectively. 
3.3 Results 
3.3.1 Transporter proteins 
For illustration, Figure 3.2 shows that the Escherichia coli gene ArtQ has large co-expression levels 
with several neighbors (ArtM, ArtI and ArtP) for the selected microarray dataset. As suggested by 
the very similar gene names, all these genes transport amino acids. Thus we predict that ArtQ also 
transports amino acid. 
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Figure 3.2 Co-expression levels of central gene ArtQ and its neighboring genes 
First, we set the number of upstream and downstream neighbors to 10 each and selected the 
3 neighbors with highest co-expression correlation. Figure 3.3 shows the results for three different 
thresholds r. 
 
Figure 3.3 Effects of the similarity threshold r of GO terms on the accuracy of transporter 
substrate classification 
When the threshold r was increased from 0.2 to 0.5, all accuracies increased likewise 
(Escherichia coli: from 87% to 90%, Saccharomyces cerevisiae: from 76% to 78%, Homo sapiens: 
from 77% to 82%). When the threshold was increased further from 0.5 to 0.8, the accuracies of 
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
PotI
(896307)
YbjO
(897212)
ArtJ
(899798)
ArtM
(900757)
ArtQ
(901473)
ArtI
(902211)
ArtP
(902957)
YbjP
(903690)
Le
ve
l o
f 
co
-e
xp
re
ss
io
n
Gene names and their start positions
50%
55%
60%
65%
70%
75%
80%
85%
90%
95%
 r = 0.2 r = 0.5 r = 0.8
A
cc
u
ra
cy
E. coli S. cerevisiae H. sapiens
38 
 
Escherichia coli and of Saccharomyces cerevisiae increased further whereas that of Homo sapiens 
decreased slightly. For Homo sapiens, more sugar transporters were incorrectly classified than 
amino acid transporters, although the number of amino acid transporters is much larger than the 
number of sugar transporters (Table 3.2). 
 
Table 3.2 Number of genes that were correctly and in-correctly classified 
Organism 
Transporter 
substrate 
r = 0.2 r = 0.5 r = 0.8 
Correctly 
classified  
Not 
correctly 
classified 
Correctly 
classified  
Not 
correctly 
classified 
Correctly 
classified  
Not 
correctly 
classified 
Escherichia 
coli 
Sugar 18 3 15 3 14 2 
Amino acid 22 3 22 1 17 1 
Saccharomyces 
cerevisiae 
Sugar 5 2 5 2 5 1 
Amino acid 11 3 10 2 7 2 
Homo sapiens Sugar 3 7 3 6 4 3 
Amino acid 30 3 28 1 15 2 
 
Next, we varied the number of neighbors while keeping the threshold r at 0.5. Figure 3.4 
shows the results for three cases where the windows sizes were (5, 3), (10, 3) and (20, 5), 
respectively. (10, 3) gave the best result for all three organisms.  
For comparison, we compared our tool against two webservers that predict substrate 
specificities of membrane transporters from the protein sequence: (1) TrSSP 
(http://bioinfo.noble.org/TrSSP/) ([151]) using the options “AAindex + PSSM based (Swissprot)” 
and (2) TransportTP (http://bioinfo3.noble.org/transporter/) ([152]) using an E-value threshold = 
0.1. The results obtained with these methods are listed in Table 3.3. Our method gave superior 
results (90% accuracy and higher) than TrSSP (64% in the best case) and TransportTP (54% in the 
best case) for Escherichia coli sequences. TransportTP did not provide useful results for 
Saccharomyces cerevisiae and human sequences. The results of TrSPP for human sequences were 
of comparable accuracy to those of our tool. For Saccharomyces cerevisiae sequences, TrSPP 
provided better results than our tool. In addition, it should be noted that our method was not able to 
make predictions for for transporters that have non-zero features (see methods; paragraph “Training 
and testing data for SVM”). 
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Table 3.3 Comparison against alternative methods for predicting substrate specificities 
Organism Group 
Number of 
sequences 
TrSSP TransportTP 
Correct Accuracy Correct Accuracy 
Escherichia coli aa 47 23 48.94% 10 21.28% 
sugar 39 25 64.10% 21 53.85% 
Saccharomyces 
cerevisiae  
aa 24 20 83,33% 0 0.00% 
sugar 17 16 94,12% 0 0.00% 
Homo sapiens aa 37 31 83,78% 0 0.00% 
sugar 13 10 76,92%   
 
 
Figure 3.4 Prediction accuracy for different window sizes 
3.3.2 Metabolic pathway enzymes 
Next we tested the same approach for the genes coding for enzymes belonging to different groups 
of metabolic pathways of Escherichia coli. Supplement table 3 shows that, when the number of 
neighbors was extended, the number of genes that can be used by SVM decreased. In consequence, 
the accuracies decreased when we considered more neighbors (Figure 3.5). This characteristic was 
not found for the transporter proteins.  
50%
55%
60%
65%
70%
75%
80%
85%
90%
95%
(5, 3) (10, 3) (20, 5)
A
cc
u
ra
cy
E. coli S. cerevisiae H. sapiens
40 
 
 
Figure 3.5 Accuracies of different thresholds r and number of neighbors when testing with 
enzymes of the sugar and amino acid metabolism 
After testing with two groups, we tested the method with the four groups of genes involved 
in sugar, amino acid, lipid, and nucleotide pathways, respectively. Figure 3.6 shows that the 
accuracies relative to the random prediction (25%) are increased compared to the previous test. 
Secondly, the threshold r had only a small effect when we extended the number of neighbors to (20, 
5). 
 
Figure 3.6 Accuracies of 4-class prediction for different thresholds and number of neighbors when testing 
with enzymes belonging to the sugar, amino acid, lipid and nucleotide metabolic pathways 
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3.4 Discussion 
The main findings of our study are: 
a) The function of membrane transporters and of metabolic enzymes is best associated with 
that of its co-expressed neighbor genes for Escherichia coli, followed by Saccharomyces 
cerevisiae, and by Homo sapiens. 
b) The substrate-specificities of membrane transporters can be classified better than the 
membership of enzymes to four major metabolic pathway classes. 
The first finding had to be expected. Operons exist in bacteria and rarely in eukaryotes 
(Saccharomyces cerevisiae and Homo sapiens). Junier and Rivoire recently reported that the 2034 
genes of Escherichia coli are arranged in 740 synteny segments [153]. They found that co-
expression occurs at high levels within synteny segments and low levels outside. However, it was 
also suggested that functionally related genes are grouped together in bacteria outside of operons in 
the form of so-called “uber-operons” [154].  
In yeast, the most highly co-expressed pairs of neighbor genes tend to be similar in function 
[133], [155] . Adjacent genes are frequently (more than 25%) transcribed in the same phase(s) of 
the cell cycle[130]. 
For Homo sapiens, Wang and colleagues recently compared the expression profiles of bulk 
tissue of glioblastoma patients to expression profiles at single-cell level [136]. Interestingly, they 
found that co-expression in bulk samples was stronger associated with similar gene function than 
that in single cell samples. In the latter case, co-expressed genes showed a stronger tendency to 
physically interact with each other. Nevertheless, our results show that the biological functions of 
co-expressed neighbor genes are in all three investigated species associated with the function of the 
central gene. 
When compared to results obtained the alternative method TrSSP, our method gave superior 
results for Escherichia coli transporters, results of comparable quality for human transporters, and 
results of slightly lower accuracy for Saccharomyces cerevisiae transporters. Since both methods 
take quasi-orthogonal approaches, it appears worthwhile to combine both methodologies in the 
future. 
Now we turn to the question why function prediction gave better results for the membrane 
transporters than for metabolic enzymes. To us, this came as a surprise. In Arabidopsis thaliana 
(which was not studied here), Ren and colleagues reported that co-functionality was in most cases 
a poor predictor of co-expression, also for neighboring genes [156]. When turned around, this 
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suggests that co-expressed and gene neighborhood cannot be taken as guarantee for co-
functionality, at least not in eukaryotic genome. 
Cui and colleagues recently analyzed correlations of the expression levels of neighboring 
genes in Homo sapiens [157]. Interestingly, they distinguished between four types of genes: 
housekeeping genes, specific and selective genes that are either preferentially or exclusively 
expressed in response to physiological stimuli, and repressed genes. Importantly, they found that 
the direction of transcription of gene pairs (parallel or antiparallel) has at most a weak effect on the 
level of co-expression. This supports the approach taken in our study where we have ignored 
directionality of genes. Compared to randomly selected gene pairs, preferentially expressed and 
repressed genes showed a substantially higher co-functionality. Interestingly, this was not the case 
for neighboring housekeeping genes and exclusively expressed gene pairs that showed an even 
lower co-functionality than randomly selected gene pairs. 
These results show that functional associations may be quite case-specific.  
3.5 Conclusion 
In this work, we focused on the classification of integral membrane transporters from three 
organisms (Escherichia coli, Saccharomyces cerevisiae and Homo sapiens) according to their 
transported substrates. The idea was to identify among the close neighbors of a query gene with 
unknown function those genes that show high co-expression with this gene. Then, we identified 
frequent GO terms among these co-expressed neighbors and used a support vector machine 
classifier to annotate the substrate specificity of the query gene. Training of the method was 
performed on groups of known amino acid and sugar transporters. For transporter proteins, the 
average accuracies of Escherichia coli, Saccharomyces cerevisiae and Homo sapiens were 89%, 
78%, and 79%, respectively. When tested on the genes belonging to different metabolic pathways 
of Escherichia coli, the average accuracy was 75% (two classes) and 67% (four classes). In future 
works, this approach may be used in combination with other features such as sequence motifs, 
sequence similarity, and further characteristics of the protein sequence such as its amino acid 
composition. 
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Chapter 4 Copy number alterations in tumor genomes deleting 
antineoplastic drug targets partially compensated by complementary 
amplifications 
 
This chapter is based on the following publication: 
Tran, V.H., Kiemer, A., Helms, V. Copy number alterations in tumor genomes deleting 
antineoplastic drug targets partially compensated by complementary amplifications. (2018) Cancer 
Genomics & Proteomics, V. 15, p. 365-378,doi: 10.21873/cgp.20095.  
My contribution was to design the research project and analyze the results together with the co-
author Volkhard Helms. I, Alexandra K. Kiemer, and Volkhard Helms prepared the manuscript. I 
collected data and performed the calculations. 
 
4.1 Introduction  
Tumor cells differ phenotypically from normal cells, for example, by showing increased levels of 
proliferation and evading apoptosis [62]. At the genomic level, one common variation of tumor 
cells are DNA copy number changes that include both gene amplifications and deletions [158]. 
When these changes occur in germline cells, they are referred to as DNA copy number variations 
(CNV). When they occur in somatic cells, they are termed copy number alterations (CNA) [32]. It 
is believed that CNAs in genome sequences of cancer patients [159] may play important roles in 
oncogenesis and cancer therapy [160].  
An important reference data set on CNAs in patients suffering from more than 30 different 
tumors was compiled by The Cancer Genome Atlas (TCGA) project. A pan-cancer study of these 
data analyzed the effect of CNAs on known oncogenic drivers and tumor suppressor genes (TSG) 
and identified potential new cancer drivers, TSGs and biomarkers [161]. This study also analyzed 
the length and the distribution of somatic CNAs along the chromosomes, identified regions that 
recurred significantly often and compared the number of genes in amplified and deleted regions 
[161]. Subsequent studies [162], [163] of CNA data from TCGA focused either on specific genes 
(e.g. PD-L1, CD247, IRS4, IGF2) or on the relationship between copy number events and gene 
expression [162], [164]. From the 33 tumor types available at TCGA today, we processed the data 
from 31 tumors in this study (glioblastoma multiforme, renal clear cell carcinoma, brain lower grade 
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glioma, lung squamous cell carcinoma, liver hepatocellular carcinoma, renal papillary cell 
carcinoma, kidney chromophobe carcinoma, breast invasive carcinoma, ovarian serous 
cystadenocarcinoma, uterine carcinosarcoma, head and neck squamous cell carcinoma, thyroid 
carcinoma, prostate adenocarcinoma, colon adenocarcinoma, stomach adenocarcinoma, bladder 
urothelial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, 
sarcoma, acute myeloid leukemia, esophageal carcinoma, pheochromocytoma and paraganglioma, 
rectum adenocarcinoma, adrenocortical carcinoma, cholangiocarcinoma, lymphoid neoplasm 
diffuse large B-cell lymphoma, uveal melanoma, mesothelioma, thymoma, testicular germ cell 
tumors, uterine corpus endometrial carcinoma, pancreatic adenocarcinoma). The original 
publications on the datasets collected for these thirty-one tumors focused on the rate of copy number 
alterations, identification of recurrently amplified/deleted CNAs, the distribution of CNAs along 
the chromosomes, identification of oncogenes and TSGs, and clustered the tumors into subtypes. 
Several follow-up studies have analyzed CNA data from TGCA and analyzed copy number changes 
[165]–[167], recurrent copy number variations/alterations [168], [169]–[171], the effect of CNAs 
on specific genes [172]–[176], identified putative new druggable cancer driver genes [177], tried to 
predict cancer relapse [178], and studied how cancer patients may be grouped into subtypes [167], 
[173]. 
Tumor therapy often involves chemotherapy [179]. The current release of Drugbank 
(version 5.0.11, downloaded on January 12, 2018) lists 477 drugs as antineoplastic (AN) agents that 
are annotated to bind to 220 different protein targets. Mapping the targets of AN agents to the 
KEGG database of cellular pathways using the tool KEGG mapper [180] shows that 53 target 
proteins from this list belong to the PI3K-Akt signaling pathway, 39 to metabolic pathways, 32 to 
the Rap1 signaling pathway, 30 to Th17 cell differentiation, 32 to the Ras signaling pathway, and 
38 to the MAPK signaling pathway. The complete list of these pathways is included as Supplement 
table 5.  
The aim of this project was to analyze how protein targets of AN agents are affected by 
CNAs. To our best knowledge, no prior study addressed a related question so far. The only related 
work we are aware of is a study by Graham et al. who recently reported that recurrent patterns of 
DNA copy number alterations in tumors reflect metabolic selection pressures such as coordinated 
alteration of genes involved in glycolytic metabolism [181]. For 31 tumor types from the TCGA 
dataset (see list above), we compared how recurrent CNAs affected the set of protein targets of 
chemotherapeutic drugs in comparison with a set of housekeeping genes and a set of cancer 
hallmark genes 
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4.2 Materials and methods 
Figure 4.1 summarizes the main steps of our analysis. 
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Figure 4.1 Main steps of analysis workflow 
4.2.1 Data on copy number alterations 
As mentioned, we analyzed genomic data from the TCGA project on CNAs observed in patients 
suffering from 31 different forms of tumors (listed in the introduction section). Missing from this 
list are the data for lung adenocarcinoma and skin cutaneous melanoma as these could not be 
processed with the GISTIC2.0 tool (see below). The CNA data of these patients (start and end 
position, chromosome, and segment mean of CNA) were downloaded from the Genomic Data 
Commons Portal (GDC portal) on September 29, 2017 [182]. 
4.2.2 Clinical data 
From the clinical data provided at GDC, we extracted information on which drug treatment was 
given to specific patients. Thereby, the presence of CNAs in individual patient genomes was 
associated with the drug treatment applied to these patients. In our work, only data from patients 
that had both CNA and clinical data available were used. 
4.2.3 Antineoplastic agents and their targets 
A list of 477 ANs together with their target proteins was extracted from Drugbank [183] (version 
5.0.11, downloaded on January 12, 2018). We considered only those protein targets for which 
46 
 
pharmacological action of the respective drug molecule is reported as “yes” in Drugbank. These 
477 AN agents are reported to bind to 220 different protein targets (labeled here by their Uniprot 
accessions numbers). After converting Uniprot accession numbers to gene symbols, we were left 
with 218 genes. As “tumor-specific” drugs, we considered those drugs that were applied to the 
patients of a particular tumor entity according to the TCGA data files. As shown in Supplement 
table 6 and Supplement table 7 for drugs against lung cancer or breast cancer, these sets comprise 
a representative subset of the FDA-approved drug treatments for these tumors types (8 out of 16 
and 23 out of 31), see https://www.cancer.gov/about-cancer/treatment/drugs/cancer-type. The sets 
for lung squamous cell carcinoma and breast cancer also included eight further drugs each that are 
not FDA-approved, but applied to TCGA patients possibly during ongoing clinical trials. Here, such 
drugs are labeled as “experimental drugs”. 
4.2.4 Gene sets 
Beside the set of protein targets of AN agents, we also considered a set of 3804 housekeeping genes 
[184] (i.e. at least one variant of these genes is expressed in all tissues uniformly; downloaded from 
https://www.tau.ac.il/~elieis/HKG/ on January 13, 2018) and a set of 2338 “hallmark genes” of 
cancer. The latter set contains all human genes that are annotated in the Gene Ontology [53] to at 
least one of 37 Gene Ontology terms that were described as hallmarks of cancer [63] (downloaded 
from http://geneontology.org/page/download-annotations on January 13, 2018). After converting 
Uniprot accession numbers to symbols, this gave 2321 gene symbols in the hallmarks of cancer 
gene set. Figure 4.2 shows the overlap of the three gene sets. 
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Figure 4.2 Overlap between the three gene sets 
4.2.5 Genes affected by copy number alterations 
Genes that are recurrently affected by CNAs were identified with the GISTIC2.0 tool version 2.0.22 
[112] using segmentation files and marker files created from the CNA data of the tumor samples. 
Following Laddha et al. [185], we used 0.2 and -0.2 as thresholds for GISTIC2.0 to identify 
recurrent amplification and deletion peaks and the genes contained in those peaks. Uniprot 
accession numbers used by Drugbank were converted to gene symbols used by GISTIC2.0 by 
making use of data from the HUGO Gene Nomenclature Committee (HGNC database) [186] that 
were downloaded in January 2017. Information on genes (chromosome, start position, and end 
position) was based on data from Ensembl (data downloaded from http://rest.ensembl.org on 
January 16, 2018). 
4.3 Results  
4.3.1 General statistics 
The aims of this work were (1) to test the hypothesis that genomic CNAs observed in tumors affect 
the protein targets of AN agents significantly more often than expected by chance, (2) to test 
whether either amplifications or deletions are more common, and (3) to study the potential 
relevance for chemoresistance. In principle, one can expect that eventually all genes except for the 
essential genes will be affected by CNAs in some patients. Hence, to get more meaningful results, 
our analysis was focused on the set of recurrently occurring CNAs that appear statistically more 
often in each individual tumor entity than expected by chance. This strategy is similar to that used 
by Graham et al. [181]. 
Table 4.1 lists the number of recurrently amplified and deleted genes obtained by processing 
the raw CNA data for the 31 considered tumors with the GISTIC2.0 program. Specified is also how 
many of these amplifications/deletions affect hallmark genes, housekeeping genes, and protein 
targets of AN drugs. Note that, in this initial analysis, protein targets of all 477 considered AN drugs 
were considered irrespective of whether these drugs are actually being used to treat the particular 
subtype of cancer. In acute myeloid leukemia, 38 of 105 cases (26.57%) received treatment prior to 
the time when the CNA data ware taken. For glioblastoma (22 of 590 cases) and renal clear cell 
carcinoma (18 of 530 cases), the number of such cases was around 4%. In all other tumors, the 
fraction of pre-treated patients was below 3 %. Hence, in all tumors except for acute myeloid 
leukemia, the detected amplifications and deletions are unlikely to reflect resistance phenomena 
occurring in response to treatment (Supplement table 8). As shown in Table 4.1, in twenty-nine out 
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of thirty-one studied tumors (the exceptions are thyroid carcinoma and kidney chromophobe), the 
number of recurrently deleted genes exceeded the number of recurrently amplified genes. However, 
this difference between the lower number of amplifications and the higher number of deletions was 
equally significant for the sets of all genes, antineoplastic targets, hallmark genes, and housekeeping 
genes (p-values 8.501e-09, 1.721e-08, 9.196e-09 and 8.367e-09, Wilcoxon test) and, hence, does 
not reflect a peculiar property of AN target genes. Supplement table 9 shows that a similar behavior 
is observed for genes annotated to specific cancer hallmarks. 
Table 4.1 Number of genes affected by CNAs in TCGA data for the 31 considered types of tumors 
Disease 
Number 
of cases 
considere
d 
Number of 
cases 
without 
pre-
treatment 
Recurrently 
amplified 
genes 
Recurrentl
y deleted 
genes 
Amplified 
AN 
targets 
Deleted 
AN 
targets 
Amplified 
Hallmark 
genes 
Deleted 
Hallmark 
genes 
Amplified 
Housekee
ping 
genes 
Deleted 
Houseke
eping 
genes 
Breast Invasive 
Carcinoma 
1094 1079 841 4084 5 34 123 605 76 304 
Glioblastoma 
Multiforme 
590 568 231 2176 4 12 20 286 20 190 
Ovarian Serous 
Cystadenocarcinoma 
570 569 470 3144 3 30 102 463 34 246 
Uterine Corpus 
Endometrial 
Carcinoma 
540 538 456 8377 3 68 84 1266 33 774 
Renal Clear Cell 
Carcinoma 
530 512 3072 5053 33 37 471 771 267 451 
Head and Neck 
Squamous Cell 
Carcinoma 
517 508 715 3166 8 31 121 455 82 238 
Brain Lower Grade 
Glioma 
514 511 628 5092 9 45 118 801 61 451 
Thyroid Carcinoma 505 500 10 4 0 0 1 1 0 1 
Lung Squamous Cell 
Carcinoma 
503 496 1154 3866 14 43 155 577 120 305 
Prostate 
Adenocarcinoma 
497 495 497 2600 2 26 70 429 30 232 
Colon 
Adenocarcinoma 
450 447 403 2364 4 23 84 317 35 193 
Stomach 
Adenocarcinoma 
442 442 1081 4124 9 41 169 641 90 407 
Bladder Urothelial 
Carcinoma 
412 402 1248 3049 12 31 232 458 134 266 
Liver Hepatocellular 
Carcinoma 
375 374 644 2818 4 28 101 388 58 223 
Cervical Squamous 
Cell Carcinoma and 
Endocervical 
Adenocarcinoma 
295 295 1506 3829 13 34 231 540 114 350 
Renal Papillary Cell 
Carcinoma 
290 290 299 6132 5 59 52 922 17 501 
Sarcoma 260 259 2602 8101 28 82 407 1201 232 759 
Acute Myeloid 
Leukemia 
143 105 3 3714 0 29 1 593 0 344 
Esophageal 
Carcinoma 
184 184 801 6773 6 61 130 1010 77 576 
Pancreatic 
Adenocarcinoma 
184 183 597 7190 6 59 87 1072 56 595 
Pheochromocytoma 
and Paraganglioma 
178 177 56 5840 1 52 9 911 5 513 
Rectum 
Adenocarcinoma 
164 163 1116 5663 9 40 190 853 92 508 
Testicular Germ Cell 
Tumors 
134 134 2142 2811 21 31 312 443 222 260 
Thymoma 124 122 0 2038 0 20 0 352 0 174 
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Kidney 
Chromophobe 
66 66 38 1 1 0 8 1 6 0 
Adrenocortical 
Carcinoma 
90 89 693 5243 4 50 93 778 66 448 
Mesothelioma 87 86 0 4357 0 43 0 681 0 464 
Uveal Melanoma 80 80 564 3050 5 33 90 465 56 342 
Lymphoid Neoplasm 
Diffuse Large B-cell 
Lymphoma 
48 47 110 6580 0 68 15 1041 10 663 
Uterine 
Carcinosarcoma 
56 56 917 4615 14 42 159 689 95 439 
Cholangiocarcinoma 36 35 19 2801 2 21 3 456 0 274 
            
Max 1094 1079 3072 8377 33 82 471 1266 267 774 
Min 36 35 0 1 0 0 0 1 0 0 
Average 321.23 316.52 739.13 4150.16 7.26 37.84 117.35 627.94 67.35 370.68 
 
4.3.2 Disease specific statistics 
For each disease, we then extracted from the GDC clinical data files the names of the drugs that 
were prescribed to the respective patients. The analysis was repeated with the same numbers of 
cases considered as in Table 4.1, but focused on the combined set of cancer-specific targets of these 
drugs, see Table 4.2. This set of target proteins was termed “specific drug targets” meaning that 
these are targets of the drugs that are given to patients with this specific tumor entity. By way of 
construction, the resulting numbers of affected genes were now far smaller. In 18 tumors, no CNA-
amplifications affected the specific drug targets. In contrast, sarcoma behaved as an outlier to the 
other extreme with eight amplified targets. In the 12 remaining tumors, only one or two cases were 
observed. In contrast, in 23 tumors, CNA-deletions affected the specific drug targets of these tumor 
types. Among the three tumors (brain lower grade glioma, sarcoma, and mesothelioma) showing 
the largest number of CNA-deleted targets (10, 14, 11) only mesothelioma showed significantly 
more deletions than amplifications (adjusted p-value of 0.001, Fisher’s exact test). When taking all 
tumor data together, the difference between specific amplified/deleted targets for the 31 tumors was 
significant (p-values of 0.00016, Wilcoxon rank-sum test). 
Table 4.2 Specific drugs and drug targets of the specified disease and the number of observed 
CNA-amplifications or CNA-deletions affecting the specific drug targets 
Disease 
Number 
of Drugs 
Number of 
targets 
proteins 
CNA-
amplified 
targets 
CNA-
deleted 
targets 
Breast Invasive Carcinoma 38 32 2 4 
Glioblastoma Multiforme 37 52 2 2 
Ovarian Serous Cystadenocarcinoma 31 19 1 3 
Uterine Corpus Endometrial Carcinoma 16 15 0 5 
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Renal Clear Cell Carcinoma 17 29 2 6 
Head and Neck Squamous Cell Carcinoma 18 20 1 3 
Brain Lower Grade Glioma 24 37 2 10 
Thyroid Carcinoma 1 1 0 0 
Lung Squamous Cell Carcinoma 16 16 2 2 
Prostate Adenocarcinoma 11 10 0 3 
Colon Adenocarcinoma 15 27 1 4 
Stomach Adenocarcinoma 22 16 0 2 
Bladder Urothelial Carcinoma 20 24 2 3 
Liver Hepatocellular Carcinoma 12 26 0 5 
Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma 
12 12 0 4 
Renal Papillary Cell Carcinoma 14 24 1 7 
Sarcoma 23 34 8 14 
Acute Myeloid Leukemia 0 0 0 0 
Esophageal Carcinoma 11 9 0 3 
Pancreatic Adenocarcinoma 15 14 1 1 
Pheochromocytoma and Paraganglioma 6 3 0 2 
Rectum Adenocarcinoma 12 9 2 0 
Testicular Germ Cell Tumors 5 1 0 0 
Thymoma 8 11 0 0 
Kidney Chromophobe 5 18 0 0 
Adrenocortical Carcinoma 10 16 0 2 
Mesothelioma 16 30 0 11 
Uveal Melanoma 1 0 0 0 
Lymphoid Neoplasm Diffuse Large B-cell 
Lymphoma 
23 15 0 4 
Uterine Carcinosarcoma 10 8 0 4 
Cholangiocarcinoma 3 2 0 0 
 
Following up on Table 4.2, Supplement table 10 lists the number of patient genomes where 
tumor-specific AN targets were affected by CNA mutations. This data shows that, although the 
absolute number of CNA-affected AN target proteins is quite small (Supplement table 10), the 
proportion of patients harboring these CNAs is in fact rather high. Respective target amplifications 
and deletions occur recurrently in a sizeable fraction (0 to 90%) of all patients. 
To get more insight into the molecular mechanisms at place, Table 4.3 and Table 4.4 list the 
gene symbols of the tumor-specific AN targets that were affected by CNA amplifications and 
deletions (Table 4.2) and the respective drugs that were applied to patients of these tumors. 
Experimental drugs were marked by label EXP, e.g. docetaxelEXP. For acute myeloid leukemia that 
contains a sizeable fraction of pre-treated patients (26.57 %) no information about the applied drugs 
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is provided in the TCGA clinical data files so that we could not identify recurrent CNA 
amplifications or deletions of cancer-specific drug targets in this case.  
Table 4.3 Gene names and corresponding drugs of specific AN targets that were recurrently 
amplified by CNAs. The drugs that bind to the respective AN target proteins are given in 
brackets. Tumors having no amplified AN targets and that are not listed in Table 4.5 are not 
shown. 
Disease Target gene (Drug name) 
Breast Invasive Carcinoma TOP2A (MitoxantroneEXP, Doxorubicin), EGFR 
(Lapatinib) 
Glioblastoma Multiforme KDR (CabozantinibEXP, SorafenibEXP), EGFR 
(ErlotinibEXP, GefitinibEXP) 
Ovarian Serous Cystadenocarcinoma VEGFA (Bevacizumab) 
Uterine Corpus Endometrial Carcinoma - 
Renal Clear Cell Carcinoma FLT4 (Sunitinib, Sorafenib, Axitinib, Pazopanib), BRAF 
(Sorafenib) 
Head and Neck Squamous Cell 
Carcinoma 
TYMS (CapecitabineEXP, PemetrexedEXP, FluorouracilEXP) 
Brain Lower Grade Glioma KIT (ImatinibEXP, SorafenibEXP), EGFR (ErlotinibEXP, 
AfatinibEXP) 
Thyroid Carcinoma - 
Lung Squamous Cell Carcinoma TYMS (Pemetrexed), EGFR (Erlotinib, Gefitinib) 
Prostate Adenocarcinoma - 
Colon Adenocarcinoma VEGFA (Aflibercept, Bevacizumab) 
Stomach Adenocarcinoma - 
Bladder Urothelial Carcinoma EGFR (ErlotinibEXP), VEGFA (BevacizumabEXP) 
Liver Hepatocellular Carcinoma - 
Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma 
- 
Renal Papillary Cell Carcinoma FLT4 (Sunitinib, Sorafenib, Pazopanib) 
Sarcoma PDGFRA (Pazopanib), HDAC2 (VorinostatEXP), FLT4 
(SorafenibEXP, Pazopanib), TUBB1 (DocetaxelEXP), KIT 
(Imatinib, SorafenibEXP, Pazopanib), KDR (SorafenibEXP, 
Pazopanib), PTGS2 (SulindacEXP), FGFR1 (SorafenibEXP) 
Pancreatic Adenocarcinoma TYMS (CapecitabineEXP, Fluorouracil) 
Rectum Adenocarcinoma TOP2A (Etoposide), VEGFA (Aflibercept, Bevacizumab) 
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Table 4.4 Names of genes that were recurrently deleted by CNAs. The drugs that bind to the 
respective AN target proteins are given in brackets. Tumors having no amplified AN targets 
and that are not listed in Table 4.3 are not shown. 
Disease Target gene (Drug name) 
Breast Invasive Carcinoma TUBA1A (Vinblastine), TUBB3 (Ixabepilone), PGR 
(Megestrol acetate), ESR2 (Tamoxifen) 
Glioblastoma Multiforme FLT1 (SorafenibEXP), FLT3 (SorafenibEXP) 
Ovarian Serous Cystadenocarcinoma RRM1 (Gemcitabine), PSMB1 (BortezomibEXP), ESR2 
(TamoxifenEXP) 
Uterine Corpus Endometrial Carcinoma RRM1 (GemcitabineEXP), PGR (Megestrol acetate), 
ESR1 (TamoxifenEXP, FulvestrantEXP), ESR2 
(TamoxifenEXP), VEGFA (BevacizumabEXP) 
Renal Clear Cell Carcinoma FLT1 (Sunitinib, Sorafenib, Axitinib, Pazopanib), 
CRBN (ThalidomideEXP), FLT3 (Sunitinib, Sorafenib), 
NR1I2 (ErlotinibEXP), RAF1 (Sorafenib), FGFR2 
(ThalidomideEXP) 
Head and Neck Squamous Cell 
Carcinoma 
RRM1 (GemcitabineEXP), BCL2 (PaclitaxelEXP), MTOR 
(EverolimusEXP) 
Brain Lower Grade Glioma TUBA1A (VinblastineEXP), TOP1MT (IrinotecanEXP), 
FLT4 (SorafenibEXP), NR1I2 (ErlotinibEXP), GSR 
(Carmustine), PDCD1 (PembrolizumabEXP), TYMS 
(CapecitabineEXP), FGFR2 (ThalidomideEXP), ESR2 
(TamoxifenEXP), FGFR1 (SorafenibEXP) 
Lung Squamous Cell Carcinoma TUBB (VincristineEXP, Vinorelbine), NR1I2 (Erlotinib) 
Prostate Adenocarcinoma LHCGR (Goserelin), MAPT (Docetaxel), CYP17A1 
(Abiraterone) 
Colon Adenocarcinoma MAPK11 (Regorafenib), TYMS (RaltitrexedEXP, 
Capecitabine, Fluorouracil, FloxuridineEXP), PGF 
(Aflibercept), FGFR2 (Regorafenib) 
Stomach Adenocarcinoma MAP2 (Docetaxel, PaclitaxelEXP), NR3C1 
(DexamethasoneEXP, MethylprednisoloneEXP) 
Bladder Urothelial Carcinoma HDAC2 (VorinostatEXP), BCL2 (PaclitaxelEXP), TUBE1 
(VinblastineEXP) 
Liver Hepatocellular Carcinoma TOP2A (DoxorubicinEXP), MAPK11 (Regorafenib), 
BRAF (Regorafenib, Sorafenib), FGFR2 (Regorafenib), 
FRK (Regorafenib) 
Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma 
MAP2(PaclitaxelEXP), TUBB1(PaclitaxelEXP), 
TOP1(Topotecan), ALPPL2(AmifostineEXP) 
Renal Papillary Cell Carcinoma IFNAR2 (Interferon Alfa-2b, RecombinantEXP), RRM1 
(GemcitabineEXP), FLT1 (Sunitinib, Sorafenib, 
Pazopanib), FLT3 (Sunitinib, Sorafenib), MS4A1 
(RituximabEXP), GART (PemetrexedEXP), IFNAR1 
(Interferon Alfa-2b, RecombinantEXP)  
Sarcoma RET (SorafenibEXP), PDGFRB (SorafenibEXP, 
Pazopanib), FLT1 (SorafenibEXP, Pazopanib), HDAC3 
(VorinostatEXP), FLT4 (SorafenibEXP, Pazopanib), BRAF 
(SorafenibEXP), TYMS (PemetrexedEXP), PTGS2 
(SulindacEXP), CYP19A1 (LetrozoleEXP), ATIC 
(PemetrexedEXP), MAP2 (DocetaxelEXP), PGR 
(Megestrol acetateEXP), MAP4 (DocetaxelEXP), FGFR1 
(SorafenibEXP) 
Acute Myeloid Leukemia   
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Esophageal Carcinoma RRM1 (GemcitabineEXP), TUBB1 (Docetaxel, 
PaclitaxelEXP), BCL2 (PaclitaxelEXP) 
Pancreatic Adenocarcinoma RRM1 (Gemcitabine) 
Pheochromocytoma and Paraganglioma RRM1 (GemcitabineEXP), TUBB (VincristineEXP) 
Adrenocortical Carcinoma RET (SorafenibEXP), BRAF (SorafenibEXP) 
Mesothelioma PDGFRB (SunitinibEXP), CSF1R (SunitinibEXP), HDAC2 
(VorinostatEXP), FLT1 (SunitinibEXP), ATIC 
(Pemetrexed), HDAC3 (VorinostatEXP), FLT3 
(SunitinibEXP), FLT4 (SunitinibEXP), TUBB 
(VinorelbineEXP), MTOR (TemsirolimusEXP, 
EverolimusEXP), VEGFA (BevacizumabEXP)  
Lymphoid Neoplasm Diffuse Large B-
cell Lymphoma 
DHFR (Methotrexate), TUBA1A (Vinblastine), 
TNFSF11 (Lenalidomide), NR3C1 (Dexamethasone, 
Prednisone, PrednisoloneEXP) 
Uterine Carcinosarcoma TUBB1 (Docetaxel, Paclitaxel), BCL2 (Paclitaxel), 
MAP4 (Docetaxel, Paclitaxel), MAPT (Docetaxel, 
Paclitaxel) 
 
Comparison of Table 4.3 and Table 4.4 reveals that for some tumors, there exist targets of 
the same drugs that were both recurrently deleted and amplified in patients of the same tumor type. 
Table 4.5 lists all such pairs. 
 
Table 4.5 Drugs that bind to amplified and deleted AN targets in a single tumor type. Names 
of target genes are given in brackets 
Disease 
Drug name (Amplified target 
genes) 
Drug name (Deleted target 
genes) 
Glioblastoma Multiforme SorafenibEXP (KDR) SorafenibEXP (FLT1, FLT3) 
Renal Clear Cell Carcinoma Sunitinib (FLT4), Sorafenib 
(FLT4, BRAF), Axitinib (FLT4), 
Pazopanib (FLT4), 
Sunitinib (FLT1, FLT3), 
Sorafenib (FLT1, FLT3, 
RAF1), Axitinib (FLT1), 
Pazopanib (FLT1) 
Brain Lower Grade Glioma ErlotinibEXP (EGFR), 
SorafenibEXP (KIT) 
ErlotinibEXP (NR1I2), 
SorafenibEXP (FLT4, 
FGFR1) 
Lung Squamous Cell 
Carcinoma 
Erlotinib (EGFR) Erlotinib (NR1I2) 
Colon Adenocarcinoma Aflibercept (VEGFA) Aflibercept (PGF) 
Renal Papillary Cell Carcinoma Sunitinib (FLT4), Sorafenib 
(FLT4), Pazopanib (FLT4) 
Sunitinib (FLT1, FLT3) 
Sorafenib (FLT1, FLT3), 
Pazopanib (FLT1) 
Sarcoma SorafenibEXP (FLT4, KIT, KDR, 
FGFR1), SulindacEXP (PTGS2), 
VorinostatEXP (HDAC2), 
DocetaxelEXP (TUBB1), 
Pazopanib (PDGFRA, FLT4, 
KIT, KDR) 
SorafenibEXP (RET, 
PDGFRB, FLT1, FLT4, 
BRAF, FGFR1), SulindacEXP 
(PTGS2), VorinostatEXP 
(HDAC3), DocetaxelEXP 
(MAP2, MAP4), Pazopanib 
(PDGFRB, FLT1, FLT4) 
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4.4 Discussion 
In this project, CNA and clinical data for 31 types of tumors from the TCGA project were combined 
with information on AN drugs from Drugbank. As shown in Table 4.1, in 29 studied tumors, the 
number of recurrently deleted genes exceeded the number of recurrently amplified genes. This 
finding is generally concordant with the results of the TCGA consortium who reported in their pan-
cancer study that the 70 peak amplification regions contained a median of 3 genes each, whereas 
70 peak regions of CNA deletions contained a median of 4 genes [161]. Earlier studies [161], [164] 
reported that CNAs promote carcinogenesis and/or tumor progression by deleting tumor suppressor 
genes (TSGs). In agreement with this, in the dataset studied here the patient genomes of 29 tumors 
contained at least one of 71 known TSGs [168] in their list of genes recurrently deleted by CNAs. 
In the case of uterine corpus endometrial carcinoma and lymphoid neoplasm diffuse large B-cell 
lymphoma, even 22 of the 71 known TSGs were recurrently affected by CNA deletions (Table 4.6). 
Table 4.6 Number of tumor suppressor genes affected by CNAs in different tumors. 
Disease 
Amplified TSG 
genes 
Deleted TSG 
genes 
Breast Invasive Carcinoma 0 12 
Glioblastoma Multiforme 1 6 
Ovarian Serous Cystadenocarcinoma 2 13 
Uterine Corpus Endometrial Carcinoma 2 22 
Renal Clear Cell Carcinoma 5 16 
Head and Neck Squamous Cell Carcinoma 0 9 
Brain Lower Grade Glioma 1 12 
Thyroid Carcinoma 0 0 
Lung Squamous Cell Carcinoma 2 9 
Prostate Adenocarcinoma 0 9 
Colon Adenocarcinoma 0 12 
Stomach Adenocarcinoma 2 13 
Bladder Urothelial Carcinoma 5 15 
Liver Hepatocellular Carcinoma 1 9 
Cervical Squamous Cell Carcinoma and Endocervical 
Adenocarcinoma 
0 10 
Renal Papillary Cell Carcinoma 1 13 
Sarcoma 6 20 
Acute Myeloid Leukemia 0 13 
Esophageal Carcinoma 0 18 
Pancreatic Adenocarcinoma 1 19 
Pheochromocytoma and Paraganglioma 0 15 
Rectum Adenocarcinoma 3 18 
Testicular Germ Cell Tumors 3 5 
Thymoma 0 4 
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Kidney Chromophobe 0 0 
Adrenocortical Carcinoma 0 13 
Mesothelioma 0 14 
Uveal Melanoma 0 10 
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma 0 22 
Uterine Carcinosarcoma 1 14 
Cholangiocarcinoma 0 10 
 
 The recurrently amplified/deleted genes of the 31 tumor types had no protein-coding gene 
in common. This is not unexpected as will be argued in the following. As shown in Table 4.1, 
recurrent CNA deletions affected on average 4150 genes, which is roughly 20% of all genes. If we 
assume that the 31 considered tumors are unrelated, we would expect that - by chance – an overlap 
of (0.2)31 × 20.000 genes = 4 × 10-28 genes would be affected in all tumor groups. This number is 
even smaller for amplified genes. This led to the expected result that all three gene sets (AN targets, 
housekeeping genes, and hallmark of the cancer genes) had no gene in common that is affected by 
CNAs in all type of tumors. 
Then, we compared how CNAs affect gene subsets comprising antineoplastic (AN) target 
genes, housekeeping genes, hallmark of cancer genes, or tumor-specific AN target genes. 
Importantly, in all these gene sets, significantly more genes were affected by deletions than by 
amplifications. Hence, this observation is not specific to AN target genes nor to tumor-specific AN 
target genes.  
The tumor-specific AN target genes recurrently affected by CNA amplifications are 
epidermal growth factor receptor (EGFR), FLT4, TYMS, TOP2A, KDR, VEGFA, BRAF, KIT, 
PDGFRA, HDAC2, TUBB1, PTGS2 and FGFR1. These genes belong to 13 types of tumors (Table 
4.1 and Table 4.3). In the 18 remaining tumor types, no tumor-specific AN target gene was 
amplified. As an example, amplifications of EGFR gene copy numbers and overexpression of 
EGFR are known to be one of the most common alterations in non-small-cell lung carcinoma 
(NSCLC) cells [187]–[190] and are associated with a poor prognosis and chemoresistance. Among 
the histological subtypes of NSCLC, EGFR is most frequently expressed in squamous cells [191].  
On the other hand, in 23 tumors, CNA-deletions affected specific drug targets of these tumor 
types. As shown in Table 4.4, CNA deletions of AN targets affected (1) the two enzymes 
bifunctional purine biosynthesis protein PURH (gene name ATIC) [192] and a subunit of 
ribonucleotide reductase (RRM1) that are both important for cell replication [193]; (2) the nuclear 
receptor NR1I2 that regulates the metabolism and efflux of xenobiotics via CYP3A4 and MDR1 
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[194]; (3) the mitochondrial and nuclear DNA topoisomerases TOP1MT and TOP2A; (4) the 
members of the vascular endothelial growth factor receptor family VEGFA, FLT1, FLT3, and (5) 
fibroblast grown factor FGFR2; (6) estrogen receptor ESR2; (7) the signaling MAP kinase 
MAPK11 and (8) the B-Raf Proto-Oncogen BRAF that regulates the MAP kinase/ERK signaling 
pathway [195]; (9) the inhibitory cell surface receptor PDCD1 that is involved in the regulation of 
T-cell function [196]; and finally (10) beta tubulin TUBB and the microtubule-associated protein 
MAP1A that is almost exclusively expressed in the brain [197], [198] (and was CNA-deleted in 
glioblastoma). As all of these proteins have important roles in promoting carcinogenesis, they have 
likely been selected as targets of antineoplastic agents. As argued above, the CNA mutations pre-
existed before the onset of the therapy.  
These findings of rare CNA amplifications, but frequent CNA deletions of tumor-specific 
drug targets have clear consequences on drug development. In future, considering CNA frequencies 
should certainly become a standard element of drug design efforts. These data also suggests that 
genomes of tumor patients may contain “compensating” mutations where one target protein of a 
drug is deleted and another target protein of the same drug is amplified. Unfortunately, due to space 
reasons we are restricted to discussing only a few of these cases in more detail. 
In renal clear cell carcinoma patients that were subsequently treated with the drug molecules 
pazopanib, sunitinib, sorafenib, and axitinib, the target protein, FLT1, of these drugs was 
recurrently deleted (in 55 samples), whereas another target protein FLT4 of the same drugs was 
recurrently amplified (in 337 samples). Overall, 36 samples had both deleted FLT1 and amplified 
FLT4. FLT4 encodes a tyrosine kinase receptor of the same protein family as vascular endothelial 
growth factors C and D. In agreement with what is expected from the observed CNA amplification, 
FLT4 was previously reported to be overexpressed in renal clear cell carcinoma [199]. Besides 
being a recurrent target of CNA deletions here, FLT1 was also reported to be frequently silenced 
through promoter hypermethylation in renal clear cell carcinoma [200]. 
In lung squamous cell carcinoma patients subsequently treated with the drug erlotinib, one 
of its targets, NR1I2, was recurrently deleted (in 20 samples) and another target, epidermal growth 
factor receptor (EGFR), was recurrently amplified (in 186 samples). Nine samples had NR1I2 
deleted and EGFR amplified at the same time. In brain lower grade glioma, NR1I2 and EGFR were 
also deleted and amplified, respectively. Beside these two genes, the target KIT of sorafenib was 
amplified while FLT4 and FGFR1 were deleted. 
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There exist also cases where the same target protein can be either amplified or deleted. For 
example, Table 4.6 shows that, FLT4 (target of sorafenib and pazopanib), and PTGS2 (target of 
sulindac) were observed to be either amplified or deleted in different sarcoma samples. FLT4 was 
amplified in 57 samples, and was deleted in 36 samples. PTGS2 was amplified in 63 samples, and 
was deleted in 32 samples. 
 
4.5  Conclusion 
The aim of this work was to test the hypothesis that the protein targets of AN agents in tumors are 
affected by genomic copy number alternations (CNAs) more strongly than expected by chance. 
Based on CNAs and clinical data from the TCGA repository, we found that the genome sequences 
of tumor patients generally contain more recurrently deleted CNAs than recurrently amplified 
CNAs. This is also the case for CNAs affecting target genes of the specific AN for these tumors. 
Interestingly, we observed certain signs of apparently compensating effects of CNAs. The data 
available for this study enabled us to identify CNA alterations that existed prior to therapy and that 
may render certain chemotherapies more or less effective. In future, it would be desirable to also 
collect time-series CNA data of tumor patients at time of diagnosis and at later time points. This 
would point to CNA alterations caused by application of certain chemotherapies and thus reflect 
chemoresistance. 
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Chapter 5 Tumor genomes frequently contain amplified resistance genes 
prior to treatment 
 
My contribution was to design the research project, analyze the results, and prepare the manuscript 
together with the co-author Volkhard Helms. I collected data and performed the calculations. 
 
5.1 Introduction  
Chemotherapy is an important and frequently applied treatment option for tumors, besides surgery 
and radiation therapy. Unfortunately, the effectiveness of chemotherapy often decreases over time 
due to the onset of drug resistance [201]. Mansoori et al. reported that 90% of failures in the 
chemotherapy are due to the invasion and metastasis of cancers related to drug resistance [202]. 
Another review on breast cancer shows that 20% to 30% of HR+ breast cancer cases resist to 
endocrine therapy. In case of HER-2+ breast cancer, de novo resistance occurred in approximately 
65% of patients, and about 70% of patients with disease that initially respond will ultimately 
develop acquired resistance [203]. The known mechanisms of drug resistance include mutations in 
the drug target, drug inactivation, epigenetic modifications, enhanced drug efflux, DNA damage 
repair, inhibition of cell death, epithelial-mesenchymal transition, aberrated activation of bypass 
pathways and abnormal downstream pathways [202], [204], [205].  
It is well established that resistance may develop subsequent to the application of 
antineoplastic agents to the patient. Here, we wondered whether the genomes of untreated tumor 
patients are “primed” in some way to develop such forms of resistance. Such data is conveniently 
available at the TCGA portal where data was primarily collected prior to treatment. As a reference 
set of resistance genes, we considered genes belonging to four antineoplastic resistance pathways 
in the KEGG database [144], [206], [207]: EGFR tyrosine kinase inhibitor resistance, endocrine 
resistance, antifolate resistance, and platinum drug resistance. The epidermal growth factor receptor 
(EGFR) is a transmembrane receptor that belongs to the family of receptor tyrosine kinases [208]. 
The activation of EGFR may lead to cancer-cell proliferation and inhibition of apoptosis [209]. 
Some FDA-approved drugs belong to tyrosine kinase inhibitor category include neratinib, 
osimertinib and neratinib. The main mechanisms of EGFR tyrosine kinase inhibitor resistance are 
EGFR mutation (drug target alteration), aberrated activation of bypass pathways, abnormal 
downstream pathways, impairment of apoptotic pathway, and epithelial-mesenchymal transition 
[205].  
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The platinum-based drugs target DNA and induce cellular apoptosis [210]. Cisplatin, the 
first platinum drug, has a strong effect initially. However, the emergence of resistance is the major 
limitation of cisplatin-base chemotherapies. Another platinum drug, carboplatin, has a similar mode 
of action and leads to similar resistance patterns as cisplatin. Carboplatin was developed in order to 
reduce the dose-limiting toxicity of cisplatin [211]. Galluzzi et al. summarized four mechanisms of 
cisplatin resistance: pre-target resistance (e.g. increase of efflux), on-target resistance (cisplatin-
resistant cells become able to tolerate unrepaired DNA lesions, or can repair adducts at an increased 
pace), post-target resistance (e.g. tumor cells can overcome apoptosis by defects in the signal 
transduction pathways), and off-target resistance [212]. To overcome resistance against cisplatin 
and carboplatin, oxaliplatin was developed. However, oxaliplatin resistance was reported to be 
accompanied by cellular influx/efflux (solute carrier superfamily of membrane transporters, copper 
transporter, and ABC transporters). The other resistance mechanisms (DNA adducts repair, 
inhibition of apoptosis) also affect the sensitivity of oxaliplatin [213]. 
Folate plays an important role in nucleotide biosynthesis and biological methylation [214]. 
Antifolates in cancer treatment interrupt the intracellular folate metabolism resulting in ineffective 
DNA synthesis [215], [216]. Reported mechanisms of antifolate resistance include: increased 
expression and mutation of target enzymes, impaired antifolate uptake, increased antifolate efflux, 
defective antifolate polyglutamylation, and the augmentation of cellular tetrahydrofolate-cofactor 
pools in cells [217], [218]. 
Estrogens are vital for regulating the growth and differentiation of normal, premalignant 
and malignant cell types through interaction with two nuclear estrogen receptors (ERalpha and 
ERbeta) [219], Consequently, these receptors became targets of endocrine therapies (e.g. 
tamoxifen) [220]. Tamoxifen is the most successful to date [221]. However, both de novo resistance 
and acquired resistance were observed in breast cancer patients [222]. Mechanisms of endocrine 
resistance include loss or modification of ER expression, epigenetics mechanisms regulating ER 
expression, regulation of signal transduction pathways, altered expression of coactivators or co-
regulators that play a critical role in ER-mediated gene transcription, altered expression of specific 
microRNAs [222].   
In the genomes of tumor patients, considerably more genes are affected by copy number 
deletions than by amplifications. This is true for the group of tumor suppressor genes, but also for 
general classes of genes such as housekeeping genes. In chapter 4, we analyzed how CNAs detected 
in the patient genomes of 31 different tumor types affect the protein targets of antineoplastic agents 
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[223]. We found that CNA deletions more frequently affected the targets of antineoplastic agents 
than CNA amplifications. In seven cancer types, we observed signs of compensatory CNAs. For 
example, in glioblastoma multiforme, two target genes (FLT1, FLT3) of the experimental drug 
sorafenib were recurrently deleted whereas another target (KDR) of sorafenib was recurrently 
amplified. In renal clear cell carcinoma, the target FLT1 of pazopanib, sunitinib, sorafenib, and 
axitinib was recurrently deleted, whereas FLT4 bound by the same drugs was recurrently amplified.  
Here, we analyzed the same data set to identify CNAs in known resistance pathways. We 
found that the number of genes in all four-resistance pathways affected by CNA amplification in 
tumor tissues is greater than in normal tissues. In contrast, there was no significant difference 
between normal and tumor tissues with respect to CNA deletions.  
5.2 Material and methods 
5.2.1 Data on copy number alterations 
As mentioned, we analyzed genomic data from the TCGA project on CNAs observed in patients 
suffering from 31 different forms of tumor. Missing from this list are the data for lung 
adenocarcinoma and skin cutaneous melanoma as these could not be processed with the GISTIC2.0 
tool (see below). The CNA data of these patients (start and end position, chromosome, and segment 
mean of CNA) were downloaded from the Genomic Data Commons Portal (GDC portal) on 
September 29, 2017 [182]. 
5.2.2 KEGG pathways for antineoplastic resistance 
From KEGG pathway (https://www.genome.jp/kegg/pathway.html), we retrieved the gene names 
of four antineoplastic drug resistance pathways. Table 5.1 shows the pathway ID, the name of the 
pathways and the number of involved genes. 
Table 5.1  Antineoplastic drug resistance pathways taken from the KEGG database 
Pathway ID Pathway name Number of Genes 
hsa01521 EGFR tyrosine kinase inhibitor resistance 79 
hsa01522 Endocrine resistance 96 
hsa01523 Antifolate resistance 31 
has01524 Platinum drug resistance 73 
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For comparison, we also retrieved the genes names of 28 unrelated KEGG pathways having a 
similar number of genes as the four resistance pathways. These pathways are listed in Supplement 
table 11. 
5.2.3 Clinical data 
From the clinical data provided at GDC, we extracted information on which drug treatment was 
given to specific patients. These lists were then intersected with information form 
https://www.cancer.gov/about-cancer/treatment/drugs/cancer-type to exclude those drugs that are 
not approved for specific cancer types.  
5.2.4 Antineoplastic agents and their targets 
A list of 477 antineoplastic (AN) agents together with their target proteins was extracted from 
Drugbank [183] (version 5.0.11, downloaded on January 12, 2018). We considered only those 
protein targets for which pharmacological action of the respective drug molecules is reported as 
“yes” in Drugbank. These 477 AN agents are reported to bind to 220 different protein targets 
(labeled here by their Uniprot accessions numbers). After converting Uniprot accession numbers to 
gene symbols, we were left with 218 genes. As shown in the previous section, we only considered 
FDA-approved drugs, and therefore we only focus on the target of these drugs. 
5.2.5 Genes affected by copy number alterations 
Genes that are recurrently affected by CNAs were identified with the GISTIC2.0 tool version 2.0.22 
[112] using segmentation files and marker files created from the CNA data of the tumor samples. 
Following Laddha et al. [185], we used 0.2 and -0.2 as thresholds for GISTIC2.0 to identify 
recurrent amplification and deletion peaks and the genes contained in those peaks. Uniprot 
accession numbers used by Drugbank were converted to gene symbols used by GISTIC2.0 by 
making use of data from the HUGO Gene Nomenclature Committee (HGNC database) [186] that 
were downloaded in January 2018.  
5.3 Results 
5.3.1 Copy number alterations affect antineoplastic drug resistance pathways 
Figure 5.1 summarizes the main steps of our analysis. 
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Figure 5.1 Workflow for analyzing effects of CNAs on genes in resistance pathways 
 
Table 5.2 - Table 5.5 summarize the number of genes in each resistance pathway that are 
recurrently affected by CNAs in normal tissues and tumor tissues. 
Table 5.2 Number of recurrently amplified resistance genes in normal tissues 
Disease hsa01521 hsa01522 hsa01523 hsa01524 
Uterine Corpus Endometrial Carcinoma 1 0 0 0 
Thyroid Carcinoma 4 3 2 3 
Prostate Adenocarcinoma 6 3 1 1 
Renal Papillary Cell Carcinoma 4 4 1 2 
Cholangiocarcinoma 1 1 0 2 
 
Table 5.3 Number of recurrently amplified resistance genes in tumor tissues 
Disease hsa01521 hsa01522 hsa01523 hsa01524 
Breast Invasive Carcinoma 3 4 1 3 
Glioblastoma Multiforme 6 3 0 1 
Ovarian Serous Cystadenocarcinoma 4 3 0 3 
Uterine Corpus Endometrial Carcinoma 5 3 0 3 
Renal Clear Cell Carcinoma 14 13 0 8 
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Head and Neck Squamous Cell Carcinoma 5 5 1 4 
Brain Lower Grade Glioma 5 6 1 2 
Lung Squamous Cell Carcinoma 6 7 2 13 
Prostate Adenocarcinoma 3 2 0 3 
Colon Adenocarcinoma 1 1 2 1 
Stomach Adenocarcinoma 7 5 1 2 
Bladder Urothelial Carcinoma 10 5 2 3 
Liver Hepatocellular Carcinoma 5 2 0 2 
Cervical Squamous Cell Carcinoma and Endocervical 
Adenocarcinoma 
8 8 1 7 
Renal Papillary Cell Carcinoma 2 2 0 1 
Sarcoma 12 10 3 11 
Esophageal Carcinoma 8 7 1 8 
Pancreatic Adenocarcinoma 4 3 1 2 
Rectum Adenocarcinoma 5 6 2 2 
Testicular Germ Cell Tumors 8 8 2 12 
Adrenocortical Carcinoma 2 4 0 2 
Uveal Melanoma 1 2 1 6 
Uterine Carcinosarcoma 3 4 1 3 
Cholangiocarcinoma 0 1 0 0 
 
Table 5.4 Number of recurrently deleted resistance genes in normal tissues 
Disease 
hsa01521 hsa01522 hsa01523 hsa01524 
Breast Invasive Carcinoma 43 43 13 34 
Glioblastoma Multiforme 18 22 6 26 
Ovarian Serous Cystadenocarcinoma 8 11 1 11 
Uterine Corpus Endometrial Carcinoma 5 4 4 6 
Renal Clear Cell Carcinoma 32 34 15 30 
Head and Neck Squamous Cell Carcinoma 42 52 13 46 
Brain Lower Grade Glioma 35 42 11 33 
Thyroid Carcinoma 14 5 6 7 
Lung Squamous Cell Carcinoma 34 30 11 17 
Prostate Adenocarcinoma 37 31 15 27 
Colon Adenocarcinoma 29 34 12 33 
Stomach Adenocarcinoma 32 25 15 30 
Liver Hepatocellular Carcinoma 6 11 2 12 
Cervical Squamous Cell Carcinoma and Endocervical 
Adenocarcinoma 
4 4 4 6 
Esophageal Carcinoma 6 5 6 10 
Pancreatic Adenocarcinoma 6 6 4 5 
Pheochromocytoma and Paraganglioma 10 8 3 12 
Thymoma 14 4 3 3 
Adrenocortical Carcinoma 26 19 14 20 
Mesothelioma 15 17 5 15 
Cholangiocarcinoma 2 0 0 0 
64 
 
 
Table 5.5 Number of recurrently deleted resistance genes in tumor tissues 
Disease hsa01521 hsa01522 hsa01523 hsa01524 
Breast Invasive Carcinoma 8 18 6 15 
Glioblastoma Multiforme 5 7 1 7 
Ovarian Serous Cystadenocarcinoma 9 10 4 9 
Uterine Corpus Endometrial Carcinoma 21 35 11 34 
Renal Clear Cell Carcinoma 19 24 5 18 
Head and Neck Squamous Cell Carcinoma 8 15 4 9 
Brain Lower Grade Glioma 14 23 5 7 
Lung Squamous Cell Carcinoma 12 19 3 15 
Prostate Adenocarcinoma 7 6 3 10 
Colon Adenocarcinoma 11 8 2 13 
Stomach Adenocarcinoma 11 20 7 9 
Bladder Urothelial Carcinoma 8 12 2 14 
Liver Hepatocellular Carcinoma 13 17 5 15 
Cervical Squamous Cell Carcinoma and Endocervical 
Adenocarcinoma 
13 21 3 11 
Renal Papillary Cell Carcinoma 18 24 7 24 
Sarcoma 23 33 8 21 
Acute Myeloid Leukemia 10 15 6 11 
Esophageal Carcinoma 25 34 9 25 
Pancreatic Adenocarcinoma 23 34 4 24 
Pheochromocytoma and Paraganglioma 16 25 6 22 
Rectum Adenocarcinoma 19 26 7 20 
Testicular Germ Cell Tumors 8 11 1 11 
Thymoma 7 13 1 5 
Adrenocortical Carcinoma 17 17 5 19 
Mesothelioma 16 19 8 24 
Uveal Melanoma 10 10 5 15 
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma 23 30 7 23 
Uterine Carcinosarcoma 17 26 5 12 
Cholangiocarcinoma 6 11 3 14 
 
In the diseases that are not listed in Table 5.2 - Table 5.5, none of the genes in the four 
considered resistance pathways was affected by CNAs. 
Then, we applied the Wilcoxon test to check whether the genes belonging to the four 
resistance pathways are comparably often affected by CNAs in normal tissues and in tumor tissues 
or not, see Table 5.6. In fact, for all resistance pathways, significantly more resistance genes were 
subject to CNA amplifications in tumor genomes than in normal genomes. On the other hand, CNA 
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deletions had similar effects on resistance genes in both tissues. As previously noticed [223], the 
number of CNA deletions generally exceeds the number of CNA amplifications.  
For comparison, we repeat the same analysis for 28 unrelated KEGG pathways of similar 
size. Apparently, very similar finding apply to these pathways as for resistance pathways: 
significantly more amplifications in tumor tissues than in normal tissues, essentially no difference 
for CNA deletions (Supplement table 12). 
Table 5.6 Adjusted P-values of Wilcoxon test 
CNA type hsa01251 hsa01522 hsa01523 hsa01524 
Amplification 1,20 x10-5 01,56 x10-6 3,74 x10-3 3,83 x10-6 
Deletion 1.000 0.105 1.000 0.499 
 
5.3.2 Copy number alterations affect antineoplastic targets 
Next, we investigated the effect of CNA amplifications on the protein targets of the four drug 
categories. The workflow for this analysis is shown in Figure 5.2. 
 
Figure 5.2 Workflow for analyzing effects of CNAs on targets of antineoplastic 
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Table 5.7 lists the number of drugs that were given to patients in each cancer type, the number 
of FDA approved drugs, and the subset of approved drugs belonging to the four resistance categories. 
The relatively small size of these subsets reflects the broad spectrum of drug targets. Table 5.8 shows 
the number of protein targets of each drug-resistance category. Table 5.9 and Table 5.10 show the 
number of targets of FDA-approved drugs affected by CNA amplifications in specific cancer types. 
Table 5.7 Number of drugs for each cancer type 
Disease All Drugs 
Approved 
Drugs 
Endocrine 
Folic 
Acid 
Platinum 
Tyrosine 
Kinase 
Inhibitor 
Breast Invasive Carcinoma 38 23 7 1 0 1 
Glioblastoma Multiforme 37 4 0 0 0 0 
Ovarian Serous Cystadenocarcinoma 31 9 0 0 2 0 
Lung Adenocarcinoma 16 9 0 1 1 2 
Uterine Corpus Endometrial Carcinoma 16 1 0 0 0 0 
Renal Clear Cell Carcinoma 17 8 0 0 0 4 
Head and Neck Squamous Cell Carcinoma 18 2 0 1 0 0 
Brain Lower Grade Glioma 24 4 0 0 0 0 
Thyroid Carcinoma 1 1 0 0 0 0 
Lung Squamous Cell Carcinoma 16 8 0 1 1 2 
Prostate Adenocarcinoma 11 8 6 0 0 0 
Skin Cutaneous Melanoma 32 9 0 0 0 0 
Colon Adenocarcinoma 15 9 0 0 1 1 
Stomach Adenocarcinoma 22 4 0 0 0 0 
Bladder Urothelial Carcinoma 20 4 0 0 1 0 
Liver Hepatocellular Carcinoma 12 2 0 0 0 2 
Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma 
12 3 0 0 0 0 
Renal Papillary Cell Carcinoma 14 6 0 0 0 3 
Sarcoma 23 4 0 0 0 1 
Acute Myeloid Leukemia 0 0 0 0 0 0 
Esophageal Carcinoma 11 1 0 0 0 0 
Pancreatic Adenocarcinoma 15 5 0 0 0 1 
Pheochromocytoma and Paraganglioma 6 0 0 0 0 0 
Rectum Adenocarcinoma 12 7 0 0 1 0 
Testicular Germ Cell Tumors 5 4 0 0 1 0 
Thymoma 8 0 0 0 0 0 
Kidney Chromophobe 5 4 0 0 0 2 
Adrenocortical Carcinoma 10 0 0 0 0 0 
Mesothelioma 16 1 0 1 0 0 
Uveal Melanoma 1 0 0 0 0 0 
Lymphoid Neoplasm Diffuse Large B-cell 
Lymphoma 
23 13 0 1 0 0 
Uterine Carcinosarcoma 10 0 0 0 0 0 
Cholangiocarcinoma 3 0 0 0 0 0 
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Table 5.8 Number of target genes in each group of approved drugs 
Disease 
Targets of 
Endocrine 
Targets of 
Folic Acid 
Targets of 
Platinum 
Targets of 
Tyrosine 
Kinase 
Inhibitor 
Breast Invasive Carcinoma 5 1 0 2 
Lung Adenocarcinoma 0 4 0 2 
Renal Clear Cell Carcinoma 0 0 0 12 
Head and Neck Squamous Cell 
Carcinoma 
0 1 0 0 
Lung Squamous Cell Carcinoma 0 4 0 2 
Prostate Adenocarcinoma 4 0 0 0 
Colon Adenocarcinoma 0 0 0 18 
Liver Hepatocellular Carcinoma 0 0 0 19 
Renal Papillary Cell Carcinoma 0 0 0 12 
Sarcoma 0 0 0 6 
Pancreatic Adenocarcinoma 0 0 0 2 
Kidney Chromophobe 0 0 0 12 
Mesothelioma 0 4 0 0 
Lymphoid Neoplasm Diffuse Large B-
cell Lymphoma 
0 1 0 0 
 
 
Table 5.9 Number of AN targets amplified by CNAs in normal tissues 
Disease 
Targets of 
Endocrine 
Targets of 
FolicAcid 
Targets of 
Platinum 
Targets of 
Tyrosine 
Kinase 
Renal Papillary Cell Carcinoma 0 0 0 3 
 
 
Table 5.10 Number of AN targets amplified by CNAs in tumor tissues 
Disease 
Targets of 
Endocrine 
Targets of 
Folic Acid 
Targets of 
Platinum 
Targets of 
Tyrosine 
Kinase 
Inhibitor 
Breast Invasive Carcinoma 0 0 0 1 
Renal Clear Cell Carcinoma 0 0 0 2 
Lung Squamous Cell Carcinoma 0 1 0 1 
Renal Papillary Cell Carcinoma 0 0 0 1 
Sarcoma 0 0 0 4 
 
The diseases that are not listed in Table 5.8 - Table 5.10 have no AN targets affected by CNAs. 
68 
 
5.4 Discussion 
In this project, CNA and clinical data for 31 types of tumors from the TCGA project were combined 
with information on AN drugs from Drugbank. As shown in Table 5.6 the difference between 
normal and tumor tissues is significant for CNA amplification but not for CNA deletions. With the 
target genes of four drug categories, only three target genes of EGFR tyrosine kinase inhibitors 
were affected by CNA amplifications in normal tissues of renal papillary cell carcinoma (Table 
5.9). In case of tumor tissues, the target genes of five diseases were affected by CNA amplifications 
(Table 5.10). 
The relation between gene amplification and drug resistance was mentioned decades ago. 
In 1984, Robert T. Schimke reported the relation of MTX resulting from the amplification of DHFR 
gene [224]. In 1991, P. Borst and R. Brown published their reviews on drug resistance and gene 
amplification. In both reviews, the authors pointed out the role of amplification of multi-drug 
resistance genes in cancer [225], [226].  Many studies since then focusing on drug resistance 
verified that gene amplifications influence drug resistance [202], [227]–[232]. Our study again 
confirms that the amplification of genes belonging to known resistance pathways in tumor tissues 
support the ability of drug resistance.  
In acute myeloid leukemia, 38 of 105 cases (26.57%) received treatment prior to the time 
when the CNA data were taken. For glioblastoma (22 of 590 cases) and renal clear cell carcinoma 
(18 of 530 cases), the number of such cases was around 4%. In all other tumors, the fraction of pre-
treated patients was below 3 %. Hence, in all tumors except for acute myeloid leukemia, the detected 
amplifications and deletions are unlikely to reflect resistance phenomena occurring in response to 
treatment (Supplement table 13). However, our result showed that, there are more amplified genes 
in resistance pathways in tumor tissues than in normal tissues, this suggest that when tumor cells 
developed, they also gained the ability of drug resistance. This type of resistance is not intrinsic 
resistance (pre-existent) neither acquired resistance (induced by drugs) (these concepts used by 
Theodor H Lippert and colleges [233]). 
Supplement table 14 - Supplement table 17 show number of cancer types that affect each 
genes in four considered resistance pathways. The first two columns of these tables show that: at 
most, only one cancer type in which CNA amplifications of normal tissues affect each genes. While 
the number of cancer types in which CNA amplifications of tumor tissues affect genes is 
significantly higher (columns 5 and 6). Some genes commonly affected by CNA amplifications in 
tumor tissues includes:  IGF1R (hsa01521, hsa01522) affected in eleven cancer types; EGFR 
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(hsa01521, hsa01522) affected in nine cancer types; PIK3CA (hsa01521, hsa01522, hsa01524) 
affected in seven cancer types; KRAS (hsa01521, hsa01522) affected in seven cancer types; GAS6 
(hsa01521), VEGFA (hsa01521) affected in seven cancer types; IKBKB (hsa01523) affected in six 
cancer types; FASLG (hsa01524), AKT3 (hsa01524), and POLH (hsa01524) affected in five cancer 
types; TYMS (hsa01523), GGH (hsa01523)  affected in three cancer types. Insulin like growth 
factor 1 receptor (IGF1R) belongs to the family of transmembrane tyrosine kinase receptors [234]. 
IGF1R play an important role in tyrosine kinase inhibitor resistance by aberrated activation of 
bypass pathway [235], [236]. Another frequently affected gene is epidermal growth factor receptor 
(EGFR). Like IGF1R, this gene also belongs to the family of receptor tyrosine kinases [208]. 
Amplifications of EGFR gene copy numbers and overexpression of EGFR are known to be one of 
the most common alterations in non-small-cell lung carcinoma (NSCLC) cells [187]–[190] and are 
associated with a poor prognosis and chemoresistance. Belong to three of four pathways (except 
hsa10523), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and 
PI3K-Akt signaling pathways can control key cellular processes involved in apoptosis, protein 
synthesis, metabolism, and cell cycle [237]–[240].The activation of this pathway also play a key 
role in drug resistance [241]–[244]. 
It is known that CNA is an mechanism for acquired resistance of chemotherapy [228], [229], 
however with the available data from TCGA we cannot argue about acquired resistance (CNA 
profile in respond to chemotherapy treatment). Integrated analysis of gene expression and 
CNVs/CNAs give promising results [245]–[247]. In future, we may apply this approach for better 
understand the mechanisms of drug resistance in cancer treatment. 
5.5 Conclusion 
To better understand cancer drug resistance, a big challenge in cancer treatment, in this work we 
provided a landscape of copy number alternations effects on four antineoplastic resistance pathways 
across 31 cancers. Based on CNAs data from the TCGA repository, we found that the genome 
sequences of tumor tissues contain more recurrently amplified CNAs of genes in antineoplastic 
resistance pathways than normal tissues. Not only the genes in the four resistance pathways, the 
targets of FDA-approved drugs also affected by tumor tissues more than normal tissues (Table 5.9 
and Table 5.10). This supports an important mechanism of drug resistance: amplification of drug 
targets. We found out that some genes (e.g. PIK3CA, EGFR, and IGF1R that play important role 
in drug resistance) affected by circa 22% to 35% cancer types (Supplement table 14 - Supplement 
table 17). In ongoing work, we are extending our analysis by combining gene expression and CNAs 
data. Because the genes only function when their corresponding proteins exist, by analyzing 
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expression data, we may have more evidence about the effect of CNAs amplification on drug 
resistance. 
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Chapter 6 Conclusions and outlook 
Presented in this thesis are three projects where we analyzed different sorts of genomic data that 
are related to transmembrane proteins, and genomic copy number alterations. We aimed to predict 
substrates which are transported by transmembrane proteins. We also investigated the effects 
caused by copy number alterations on the target protein of antineoplastic agents, and on the genes 
in antineoplastic resistance pathways in cancer patients. 
In the first project, we proposed a computational method to classify membrane transporters 
from three organisms (Escherichia coli, Saccharomyces cerevisiae and Homo sapiens) according 
to their transported substrates. Promoted by the idea of operon, our method focuses of neighboring 
genes that show high co-expression with the query gene. Then, we identified frequent GO terms 
among these co-expressed neighbors and used a support vector machine classifier to annotate the 
substrate specificity of the query gene. For transporter proteins from Escherichia coli, 
Saccharomyces cerevisiae and Homo sapiens, the average accuracies were 89%, 78%, and 79%, 
respectively. When tested on the genes belonging to different metabolic pathways of Escherichia 
coli, the average accuracy was 75% (two classes) and 67% (four classes). This suggests that transfer 
of functional associations between co-expressed neighboring genes may be case-specific. In future 
works, this approach may be used in combination with other features such as sequence motifs, 
sequence similarity, and further characteristics of the protein sequence such as its amino acid 
composition. 
The second project aimed at testing the hypothesis that the protein targets of AN agents in 
tumors are affected by genomic copy number alternations (CNAs) more strongly than expected by 
chance. By analyzing CNAs and clinical data of 31 tumor types from TCGA, we found that the 
genome sequences of tumor patients generally contain more recurrently deleted CNAs than 
recurrently amplified CNAs. This is also the case for CNAs affecting target genes of the specific 
AN for these tumors. We observed certain signs of apparently compensating effects of CNAs. For 
example, in glioblastoma multiforme, two target genes (FLT1, FLT3) of the experimental drug 
sorafenib were recurrently deleted whereas another target (KDR) of sorafenib was recurrently 
amplified. In renal clear cell carcinoma, the target FLT1 of pazopanib, sunitinib, sorafenib, and 
axitinib was recurrently deleted, whereas FLT4 bound by the same drugs was recurrently amplified. 
The data available for this study enabled us to identify CNA alterations that existed prior to therapy 
and that may render certain chemotherapies more or less effective. In future, it would be desirable 
to also collect time-series CNA data of tumor patients at time of diagnosis and at later time points. 
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This would point to CNA alterations caused by the application of certain chemotherapies and thus 
reflect chemoresistance. 
The third project continues the idea of chemoresistance as suggested in the second one. We 
still used CNAs data from the TCGA repository, but not only data from tumor tissues like in the 
second project. In the third project, we utilized CNAs data from both normal and tumor tissues. We 
found that the genome sequences of tumor tissues contain more recurrently amplified CNAs of 
genes in antineoplastic resistance pathways than normal tissues. AN targets of FDA-approved drugs 
were amplified in normal tissues of only one cancer type (Table 5.9) while they were amplified in 
tumor tissues of five cancer types (Table 5.10). This is in support for an important mechanism of 
drug resistance: amplification of drug targets. We also found out that some genes (e.g. PIK3CA, 
EGFR, and IGF1R) play important roles in drug resistance and were affected by circa 22% to 35% 
cancer types. In future work, this analysis may be extended by combining gene expression data and 
CNA data. The genes only function when they are expressed. Hence, by analyzing expression data, 
we may have more evidence about the effect of CNAs amplification on drug resistance. 
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Supplementary material 
 
Supplement table 1: Gene symbols of four metabolic pathway groups 
Amino Acid Sugar Lipid Nucleotide 
gstA, ygfK, hcaB, 
hcaC, ygfM, hcaE, 
luxS, katG, sdaA, 
sdaB, mmuM, astC, 
astB, astE, astD, 
malY, patD, pheA, 
gdhA, lysA, ynfE, 
ynfF, lysC, hcaF, 
asd, adiA, argC, 
argB, tdcG, argE, 
argD, mhpE, argA, 
gor, tdcB, argG, 
mhpD, argF, mhpC, 
argI, mhpB, argH, 
mhpA, pepN, pepA, 
pepB, sufS, pepD, 
ilvD, hisB, ilvC, 
hisC, hisD, ilvE, 
hisF, hisG, hisH, 
hisI, ynjE, ilvA, 
hisA, trpD, trpE, 
trpB, trpC, sseA, 
tynA, xdhD, gshA, 
gshB, trpA, cysK, 
puuD, proA, proB, 
proC, dsdA, puuA, 
cysE, puuB, gss, 
puuC, selA, cadA, 
cysM, selD, dapA, 
dapB, putA, feaB, 
ansB, ansA, dapE, 
dapF, dapD, alaA, 
mnaT, nadB, tyrA, 
tyrB, asnA, asnB, 
avtA, panC, panD, 
ydiB, paaD, aroK, 
paaE, paaG, aroL, 
dcyD, aroG, paaA, 
aroF, paaB, paaC, 
aroH, murE, aroC, 
yjhH, aroB, murD, 
ldcC, aroE, murC, 
aroD, murI, paaI, 
paaJ, aroA, murF, 
bcsA, fruA, fruB, 
manY, manX, aceF, 
aceE, ugd, sucC, 
manA, sucD, cmtB, 
scpB, rhmD, frdA, 
cmtA, frdB, ppsA, 
gapA, frdC, frdD, 
rhmA, glf, glk, xylA, 
xylB, malZ, aceB, 
malX, chiA, aceA, 
fdhF, ebgC, yeaD, 
ebgA, amyA, acuI, 
gmd, yedP, tpiA, 
garL, glgX, garR, 
glxR, glgB, glgC, 
garD, rbsK, glgP, 
ppc, ldhA, bcsZ, 
uxuB, appA, glgA, 
fruK, manZ, bglA, 
bglB, uxuA, ghrB, 
rhaB, rhaA, agaI, 
agaD, tdcE, agaC, 
tdcD, agaB, suhB, 
rhaD, gatY, acs, 
agaV, gatA, gatB, 
gatD, gph, nanK, 
fumA, fumB, talA, 
fumC, talB, nanA, 
nanE, fdoI, sdhD, 
fdoH, pck, sdhC, 
fdoG, purU, dld, 
sdhB, sdhA, otsB, 
ulaA, eno, otsA, 
yccX, ttdB, ulaF, 
ulaG, ttdA, ulaD, 
ulaE, ulaB, ulaC, 
gatZ, gcd, agp, ptsG, 
mtlD, mtlA, gcl, 
lyxK, glmM, acnA, 
acnB, glmU, yiaK, 
maeB, maeA, hchA, 
eutG, eutE, eutD, 
tktA, tktB, fbp, pfo, 
poxB, sgbE, treF, 
fabI, fabH, fabG, 
plsC, fabZ, plsB, 
dhaL, dhaK, cdh, 
aslA, fabF, glpK, 
fabD, fabB, fabA, 
glpQ, yciA, pgpA, 
pgpB, pgpC, psd, 
ugpQ, glpA, glpB, 
glpC, glpD, ynbB, 
eutC, eutB, pgsA, 
aas, eutA, dgkA, 
tesB, cdsA, gpsA, 
tesA, pldA, pldB, 
fadE, fadD, plsX, 
plsY, clsB, clsA 
dut, hiuH, cysC, 
dnaX, nrdB, nrdA, 
tmk, nrdF, nrdE, 
nrdD, dnaE, cdd, 
apt, pnp, upp, dnaQ, 
dnaN, guaC, cmk, 
guaD, xapA, gmk, 
rpoB, rpoA, rpoC, 
paoB, dgt, paoC, 
paoA, rdgB, umpG, 
nudF, nudE, apaH, 
guaA, guaB, rihB, 
thyA, hpt, ndk, ppx, 
psuG, psuK, holE, 
mazG, polA, add, 
ade, cpdB, gpp, adk, 
gpt, holA, holB, 
holC, holD, rpoZ, 
udk, udp, ushA, 
amn, dcd, purT, 
purM, purN, yjjG, 
spoT, deoD, cyaA, 
deoA, rutF, rutE, 
purC, purD, rutB, 
rutA, rutD, rutC, 
pyrE, allE, pyrF, 
purK, pyrG, purL, 
pyrH, purE, allB, 
allA, allD, pyrC, 
purH, allC, pyrD, 
tdk, xdhA, relA, gsk, 
xdhB, xdhC 
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paaK, yafJ, ggt, 
dadX, phnJ, phnL, 
phnM, phnG, mtn, 
phnH, alr, phnI, 
aspC, speE, speD, 
speG, tauD, speF, 
speA, aspA, speC, 
phnP, speB, thrB, 
thrC, dadA, thrA, 
ltaE, gltB, metL, 
gltD, patA, tnaA, 
dcm, astA, serA, 
metC, metB, serC, 
metA, serB, metG, 
metE, metK, metH, 
glsA, glsB, kbl, 
ddlB, tdh, ddlA, 
betA, yagE, paaZ, 
betB 
mqo, treC, treA, 
treB, gntK, sgbH, 
cpsG, dgoK, ydjG, 
pgi, pgl, pgk, yadI, 
mak, dgoD, dgoA, 
prpB, prpC, prpD, 
prpE, fucI, chbF, 
fucK, gloA, gloB, 
fucO, ydiF, cpsB, 
hyi, mgsA, fucA, 
rpiB, kbaZ, nagE, 
rpiA, galE, nagK, 
murA, galK, galM, 
murB, ycjU, alsK, 
fbaB, fbaA, ybhJ, 
ycjM, pfkA, pfkB, 
oxc, ybhC, kbaY, 
nagB, nagA, sgcC, 
eda, edd, sgcB, 
sgcA, arnB, arnA, 
arnD, arnC, phnN, 
alsE, dmlA, sgbU, 
wecC, kduD, wecB, 
glpX, kduI, srlB, 
srlA, yihQ, gltA, 
srlD, yihU, uidA, 
malS, idnK, malQ, 
malP, yqhD, srlE, 
uxaB, lldD, uxaC, 
glcB, uxaA, glcD, 
glcE, ascF, glcF, 
araD, deoC, ascB, 
araA, araB, crr, 
aldB, wcaG, aldA, 
rpe, rspB, rspA, 
wcaN, kdgK, ybiW, 
yagH, galT, galU, 
murQ, nagZ, murP, 
pflB, pflD, gudD 
  
96 
 
 
Supplement table 2 Usable membrane proteins when retrieving 10 neighbors upstream, 10 
neighbors downstream and selecting 3 neighbors that have highest co-expression correlations 
Threshold r 
Organism Gene group Total 
No 
neighbors 
No 
expression 
Not usable 
for SVM 
Usable 
for SVM 
0.2 Escherichia coli Sugar 39 0 10 8 21 
Amino acid 47 0 14 8 25 
Saccharomyces 
cerevisiae 
Sugar 17 0 10 0 7 
Amino acid 24 0 10 0 14 
Homo sapiens Sugar 13 1 0 2 10 
Amino acid 37 3 1 0 33 
0.5 Escherichia coli Sugar 39 0 10 11 18 
Amino acid 47 0 14 10 23 
Saccharomyces 
cerevisiae 
Sugar 17 0 10 0 7 
Amino acid 24 0 10 2 12 
Homo sapiens Sugar 13 1 0 3 9 
Amino acid 37 3 1 4 29 
0.8 Escherichia coli Sugar 39 0 10 13 16 
Amino acid 47 0 14 15 18 
Saccharomyces 
cerevisiae 
Sugar 17 0 10 1 6 
Amino acid 24 0 10 5 9 
Homo sapiens Sugar 13 1 0 5 7 
Amino acid 37 3 1 16 17 
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Supplement table 3 Two groups of metabolic pathway enzymes with different thresholds and 
number of neighbors 
Threshold 
r 
Windows size Gene group Total 
No 
neighbors 
No 
expression 
Not usable 
for SVM 
Usable for 
SVM 
0.2 (5, 3) Sugar 253 6 52 50 145 
Amino acid 187 2 40 44 101 
(10, 3) Sugar 253 6 52 88 107 
Amino acid 187 2 40 72 73 
(20, 5) Sugar 253 6 52 118 77 
Amino acid 187 2 40 104 41 
0.5 (5, 3) Sugar 253 6 52 51 144 
Amino acid 187 2 40 49 96 
(10, 3) Sugar 253 6 52 89 106 
Amino acid 187 2 40 75 70 
(20, 5) Sugar 253 6 52 118 77 
Amino acid 187 2 40 105 40 
0.8 (5, 3) Sugar 253 6 52 59 136 
Amino acid 187 2 40 52 93 
(10, 3) Sugar 253 6 52 92 103 
Amino acid 187 2 40 77 68 
(20, 5) Sugar 253 6 52 120 75 
Amino acid 187 2 40 105 40 
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Supplement table 4 Four groups of metabolic pathway enzymes with different thresholds and 
number of neighbors 
Threshold 
r Windows size Gene group Total 
No 
neighbors 
No 
expression 
Not 
usable 
for SVM 
Usable for 
SVM 
0.2 (5, 3) Sugar 253 6 52 65 130 
Amino acid 187 2 40 51 94 
Lipid 45 1 8 14 22 
Nucleotide 99 2 26 21 50 
(10, 3) Sugar 253 6 52 132 63 
Amino acid 187 2 40 101 44 
Lipid 45 1 8 26 10 
Nucleotide 99 2 26 37 34 
(20, 5) Sugar 253 6 52 157 38 
Amino acid 187 2 40 127 18 
Lipid 45 1 8 32 4 
Nucleotide 99 2 26 49 22 
0.5 (5, 3) Sugar 253 6 52 67 128 
Amino acid 187 2 40 52 93 
Lipid 45 1 8 15 21 
Nucleotide 99 2 26 21 50 
(10, 3) Sugar 253 6 52 132 63 
Amino acid 187 2 40 101 44 
Lipid 45 1 8 26 10 
Nucleotide 99 2 26 38 33 
(20, 5) Sugar 253 6 52 157 38 
Amino acid 187 2 40 127 18 
Lipid 46 1 8 33 4 
Nucleotide 99 2 26 49 22 
0.8 (5, 3) Sugar 253 6 52 67 128 
Amino acid 187 2 40 52 93 
Lipid 45 1 8 16 20 
Nucleotide 99 2 26 25 46 
(10, 3) Sugar 253 6 52 132 63 
Amino acid 187 2 40 101 44 
Lipid 45 1 8 26 10 
Nucleotide 99 2 26 39 32 
(20, 5) Sugar 253 6 52 157 38 
Amino acid 187 2 40 127 18 
Lipid 45 1 8 32 4 
Nucleotide 99 2 26 49 22 
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Supplement table 5 KEGG pathways that contain target proteins of antineoplastic drugs 
Pathway ID Pathway name Number of AN targets 
hsa05200 Pathways in cancer 70 
hsa04151 PI3K-Akt signaling pathway 53 
hsa01100 Metabolic pathways 39 
hsa04010 MAPK signaling pathway 38 
hsa05165 Human papillomavirus infection 36 
hsa04060 Cytokine-cytokine receptor interaction 35 
hsa04014 Ras signaling pathway 32 
hsa04015 Rap1 signaling pathway 32 
hsa04659 Th17 cell differentiation 30 
hsa05166 HTLV-I infection 27 
hsa05205 Proteoglycans in cancer 26 
hsa04510 Focal adhesion 26 
hsa04630 Jak-STAT signaling pathway 25 
hsa05206 MicroRNAs in cancer 24 
hsa05167 Kaposi's sarcoma-associated herpesvirus infection 24 
hsa04640 Hematopoietic cell lineage 24 
hsa01521 EGFR tyrosine kinase inhibitor resistance 24 
hsa05203 Viral carcinogenesis 22 
hsa05224 Breast cancer 21 
hsa04658 Th1 and Th2 cell differentiation 21 
hsa04660 T cell receptor signaling pathway 21 
hsa04810 Regulation of actin cytoskeleton 21 
hsa05164 Influenza A 20 
hsa04380 Osteoclast differentiation 20 
hsa00230 Purine metabolism 20 
hsa05162 Measles 20 
hsa05215 Prostate cancer 19 
hsa05034 Alcoholism 19 
hsa05226 Gastric cancer 18 
hsa05230 Central carbon metabolism in cancer 18 
hsa05223 Non-small cell lung cancer 18 
hsa05161 Hepatitis B 18 
hsa04210 Apoptosis 18 
hsa04919 Thyroid hormone signaling pathway 18 
hsa04620 Toll-like receptor signaling pathway 17 
hsa04024 cAMP signaling pathway 17 
hsa01522 Endocrine resistance 17 
hsa04540 Gap junction 17 
hsa05152 Tuberculosis 16 
hsa05202 Transcriptional misregulation in cancer 16 
hsa05323 Rheumatoid arthritis 16 
hsa04917 Prolactin signaling pathway 15 
hsa04933 AGE-RAGE signaling pathway in diabetic complications 15 
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hsa05218 Melanoma 15 
hsa05220 Chronic myeloid leukemia 15 
hsa04066 HIF-1 signaling pathway 15 
hsa05212 Pancreatic cancer 15 
hsa04012 ErbB signaling pathway 14 
hsa04550 Signaling pathways regulating pluripotency of stem cells 14 
hsa04650 Natural killer cell mediated cytotoxicity 14 
hsa05142 Chagas disease (American trypanosomiasis) 14 
hsa05214 Glioma 14 
hsa05225 Hepatocellular carcinoma 14 
hsa05221 Acute myeloid leukemia 14 
hsa05418 Fluid shear stress and atherosclerosis 13 
hsa05160 Hepatitis C 13 
hsa04370 VEGF signaling pathway 13 
hsa05219 Bladder cancer 13 
hsa05169 Epstein-Barr virus infection 13 
hsa05140 Leishmaniasis 13 
hsa05222 Small cell lung cancer 13 
hsa04921 Oxytocin signaling pathway 13 
hsa04218 Cellular senescence 13 
hsa04621 NOD-like receptor signaling pathway 13 
hsa04926 Relaxin signaling pathway 13 
hsa04722 Neurotrophin signaling pathway 13 
hsa05168 Herpes simplex infection 12 
hsa04072 Phospholipase D signaling pathway 12 
hsa05133 Pertussis 12 
hsa00240 Pyrimidine metabolism 12 
hsa04064 NF-kappa B signaling pathway 12 
hsa04662 B cell receptor signaling pathway 12 
hsa04514 Cell adhesion molecules (CAMs) 12 
hsa04217 Necroptosis 12 
hsa05145 Toxoplasmosis 12 
hsa04360 Axon guidance 12 
hsa04912 GnRH signaling pathway 12 
hsa04657 IL-17 signaling pathway 12 
hsa05231 Choline metabolism in cancer 12 
hsa04664 Fc epsilon RI signaling pathway 12 
hsa04668 TNF signaling pathway 11 
hsa05216 Thyroid cancer 11 
hsa04726 Serotonergic synapse 11 
hsa04071 Sphingolipid signaling pathway 11 
hsa04062 Chemokine signaling pathway 11 
hsa04150 mTOR signaling pathway 11 
hsa04068 FoxO signaling pathway 11 
hsa04145 Phagosome 11 
hsa04913 Ovarian steroidogenesis 10 
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hsa04915 Estrogen signaling pathway 10 
hsa05321 Inflammatory bowel disease (IBD) 10 
hsa04144 Endocytosis 10 
hsa04080 Neuroactive ligand-receptor interaction 10 
hsa05130 Pathogenic Escherichia coli infection 9 
hsa05340 Primary immunodeficiency 9 
hsa04750 Inflammatory mediator regulation of TRP channels 9 
hsa05213 Endometrial cancer 9 
hsa04371 Apelin signaling pathway 9 
hsa05211 Renal cell carcinoma 9 
hsa04270 Vascular smooth muscle contraction 9 
hsa01523 Antifolate resistance 9 
hsa04520 Adherens junction 8 
hsa04920 Adipocytokine signaling pathway 8 
hsa04020 Calcium signaling pathway 8 
hsa04910 Insulin signaling pathway 8 
hsa04720 Long-term potentiation 8 
hsa04672 Intestinal immune network for IgA production 8 
hsa05120 Epithelial cell signaling in Helicobacter pylori infection 8 
hsa05131 Shigellosis 8 
hsa03410 Base excision repair 8 
hsa04916 Melanogenesis 8 
hsa00140 Steroid hormone biosynthesis 8 
hsa05210 Colorectal cancer 8 
hsa04530 Tight junction 8 
hsa04611 Platelet activation 8 
hsa04666 Fc gamma R-mediated phagocytosis 8 
hsa04932 Non-alcoholic fatty liver disease (NAFLD) 8 
hsa04730 Long-term depression 8 
hsa04914 Progesterone-mediated oocyte maturation 7 
hsa05146 Amoebiasis 7 
hsa05410 Hypertrophic cardiomyopathy (HCM) 7 
hsa04140 Autophagy - animal 7 
hsa05132 Salmonella infection 7 
hsa04022 cGMP-PKG signaling pathway 7 
hsa05020 Prion diseases 7 
hsa05414 Dilated cardiomyopathy (DCM) 6 
hsa04725 Cholinergic synapse 6 
hsa04670 Leukocyte transendothelial migration 6 
hsa04114 Oocyte meiosis 6 
hsa04110 Cell cycle 6 
hsa05010 Alzheimer's disease 6 
hsa05031 Amphetamine addiction 6 
hsa03050 Proteasome 6 
hsa01524 Platinum drug resistance 6 
hsa05030 Cocaine addiction 5 
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hsa04931 Insulin resistance 5 
hsa04622 RIG-I-like receptor signaling pathway 5 
hsa03030 DNA replication 5 
hsa05032 Morphine addiction 5 
hsa04940 Type I diabetes mellitus 5 
hsa05332 Graft-versus-host disease 5 
hsa05330 Allograft rejection 5 
hsa05143 African trypanosomiasis 5 
hsa00480 Glutathione metabolism 5 
hsa04728 Dopaminergic synapse 5 
hsa05416 Viral myocarditis 5 
hsa05134 Legionellosis 5 
hsa04930 Type II diabetes mellitus 5 
hsa04723 Retrograde endocannabinoid signaling 5 
hsa05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 5 
hsa04724 Glutamatergic synapse 5 
hsa04261 Adrenergic signaling in cardiomyocytes 5 
hsa04115 p53 signaling pathway 5 
hsa04512 ECM-receptor interaction 5 
hsa05144 Malaria 5 
hsa04310 Wnt signaling pathway 4 
hsa05320 Autoimmune thyroid disease 4 
hsa04623 Cytosolic DNA-sensing pathway 4 
hsa05014 Amyotrophic lateral sclerosis (ALS) 4 
hsa00590 Arachidonic acid metabolism 4 
hsa04925 Aldosterone synthesis and secretion 4 
hsa05322 Systemic lupus erythematosus 4 
hsa03420 Nucleotide excision repair 4 
hsa00670 One carbon pool by folate 4 
hsa04713 Circadian entrainment 3 
hsa04960 Aldosterone-regulated sodium reabsorption 3 
hsa00330 Arginine and proline metabolism 3 
hsa04213 Longevity regulating pathway - multiple species 3 
hsa00983 Drug metabolism - other enzymes 3 
hsa05100 Bacterial invasion of epithelial cells 3 
hsa03320 PPAR signaling pathway 3 
hsa04350 TGF-beta signaling pathway 3 
hsa05150 Staphylococcus aureus infection 3 
hsa04727 GABAergic synapse 3 
hsa04340 Hedgehog signaling pathway 3 
hsa00350 Tyrosine metabolism 3 
hsa04612 Antigen processing and presentation 2 
hsa04137 Mitophagy - animal 2 
hsa00260 Glycine, serine and threonine metabolism 2 
hsa05310 Asthma 2 
hsa00340 Histidine metabolism 2 
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hsa04924 Renin secretion 2 
hsa05016 Huntington's disease 2 
hsa00790 Folate biosynthesis 2 
hsa05110 Vibrio cholerae infection 2 
hsa00565 Ether lipid metabolism 2 
hsa00982 Drug metabolism - cytochrome P450 2 
hsa00380 Tryptophan metabolism 2 
hsa04971 Gastric acid secretion 2 
hsa04330 Notch signaling pathway 2 
hsa04961 Endocrine and other factor-regulated calcium reabsorption 2 
hsa04152 AMPK signaling pathway 2 
hsa00360 Phenylalanine metabolism 2 
hsa04211 Longevity regulating pathway 2 
hsa00592 alpha-Linolenic acid metabolism 2 
hsa00591 Linoleic acid metabolism 2 
hsa00564 Glycerophospholipid metabolism 2 
hsa04918 Thyroid hormone synthesis 2 
hsa04966 Collecting duct acid secretion 1 
hsa00190 Oxidative phosphorylation 1 
hsa04390 Hippo signaling pathway 1 
hsa05012 Parkinson's disease 1 
hsa05204 Chemical carcinogenesis 1 
hsa00860 Porphyrin and chlorophyll metabolism 1 
hsa04972 Pancreatic secretion 1 
hsa04911 Insulin secretion 1 
hsa03010 Ribosome 1 
hsa00760 Nicotinate and nicotinamide metabolism 1 
hsa00730 Thiamine metabolism 1 
hsa00450 Selenocompound metabolism 1 
hsa04922 Glucagon signaling pathway 1 
hsa05217 Basal cell carcinoma 1 
hsa00270 Cysteine and methionine metabolism 1 
hsa00120 Primary bile acid biosynthesis 1 
hsa04215 Apoptosis - multiple species 1 
hsa04976 Bile secretion 1 
hsa04141 Protein processing in endoplasmic reticulum 1 
hsa04070 Phosphatidylinositol signaling system 1 
hsa04923 Regulation of lipolysis in adipocytes 1 
hsa04136 Autophagy - other 1 
hsa00900 Terpenoid backbone biosynthesis 1 
hsa04970 Salivary secretion 1 
hsa04610 Complement and coagulation cascades 1 
hsa04721 Synaptic vesicle cycle 1 
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Supplement table 6 Drugs applied against Lung Carcinoma. The first column contains FDA-approved 
drugs against Non-Small Cell Lung Cancer (58 drugs). The second column contains a subset of the drugs 
from the first column after removing duplicated ones (25 drugs). The third column contains drugs that 
were applied to Lung Squamous Cell Carcinoma patients in TCGA (16 drugs). The drugs marked in red 
are found in both column (2 and 3). Eight of sixteen drugs applied to Lung Squamous Cell Carcinoma 
patients in the TCGA panel were FDA-approved. 
Approved drugs from Cancer.org Compact list of approved drugs 
Drugs applied 
for patients in 
TCGA 
Methotrexate Methotrexate 
  
  
  
  
  
  
Erlotinib 
Methotrexate LPF (Methotrexate) Paclitaxel 
Mexate (Methotrexate) Vincristine 
Mexate-AQ (Methotrexate) Pemetrexed 
Abitrexate (Methotrexate) Topotecan 
Folex (Methotrexate) Doxorubicin 
Folex PFS (Methotrexate) Gemcitabine 
Paclitaxel Paclitaxel 
  
  
  
Oxaliplatin 
Paclitaxel Albumin-stabilized Nanoparticle 
Formulation 
Docetaxel 
Abraxane (Paclitaxel Albumin-stabilized 
Nanoparticle Formulation) 
Gefitinib 
Taxol (Paclitaxel) Vinorelbine 
Afatinib Dimaleate Afatinib Dimaleate 
  
Carboplatin 
Gilotrif (Afatinib Dimaleate) Irinotecan 
Everolimus Everolimus 
  
Cisplatin 
Afinitor (Everolimus) Temozolomide 
Alectinib Alectinib 
  
Etoposide 
Alecensa (Alectinib)   
Pemetrexed Disodium Pemetrexed Disodium 
  
  
Alimta (Pemetrexed Disodium)   
Brigatinib Brigatinib 
  
  
Alunbrig (Brigatinib)   
Atezolizumab Atezolizumab 
  
  
Tecentriq (Atezolizumab)   
Bevacizumab Bevacizumab 
  
  
Avastin (Bevacizumab)   
Carboplatin Carboplatin 
  
  
  
Paraplat (Carboplatin)   
Paraplatin (Carboplatin)   
Ceritinib Ceritinib 
  
  
Zykadia (Ceritinib)   
Crizotinib Crizotinib 
  
  
Xalkori (Crizotinib)   
Ramucirumab Ramucirumab 
  
  
Cyramza (Ramucirumab)   
Dabrafenib Dabrafenib 
  
  
Tafinlar (Dabrafenib)   
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Docetaxel Docetaxel 
  
  
Taxotere (Docetaxel)   
Erlotinib Hydrochloride Erlotinib Hydrochloride 
  
  
Tarceva (Erlotinib Hydrochloride)   
Gemcitabine Hydrochloride Gemcitabine Hydrochloride 
  
  
Gemzar (Gemcitabine Hydrochloride)   
Gefitinib Gefitinib 
  
  
Iressa (Gefitinib)   
Pembrolizumab Pembrolizumab 
  
  
Keytruda (Pembrolizumab)   
Mechlorethamine Hydrochloride Mechlorethamine Hydrochloride 
  
  
Mustargen (Mechlorethamine Hydrochloride)   
Trametinib Trametinib 
  
  
Mekinist (Trametinib)   
Vinorelbine Tartrate Vinorelbine Tartrate 
  
  
Navelbine (Vinorelbine Tartrate)   
Necitumumab Necitumumab 
  
  
Portrazza (Necitumumab)   
Nivolumab Nivolumab 
  
  
Opdivo (Nivolumab)   
Osimertinib Osimertinib 
  
  
Tagrisso (Osimertinib)   
 
According to https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-
lung-cancer.html, Lung Squamous Cell Carcinoma is a sub-type of Non-Small Cell Lung Cancer. 
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Supplement table 7 Drugs against breast cancer. The first column contains FDA-approved drugs against 
breast cancer (71), the second column contains the compact list after removing duplicates (31 drugs), 
and the third column contains drugs that were applied to patients in the TCGA panel (38). The drugs 
marked in red are found in both column (2 and 3). 23 out of 38 drugs applied to TCGA-patients were 
FDA-approved drugs. 
Approved drugs from Cancer.org 
Compact list of approved 
drugs 
Drugs applied for 
patients in TCGA 
Abemaciclib Abemaciclib Tamoxifen 
Verzenio (Abemaciclib) Anastrozole 
Methotrexate Methotrexate Paclitaxel 
Abitrexate (Methotrexate) Toremifene 
Folex (Methotrexate) Vincristine 
Folex PFS (Methotrexate) Fluorouracil 
Methotrexate LPF (Methotrexate) Capecitabine 
Mexate (Methotrexate) Doxorubicin 
Mexate-AQ (Methotrexate) Letrozole 
Paclitaxel Paclitaxel Pegfilgrastim 
Paclitaxel Albumin-stabilized Nanoparticle 
Formulation 
Vinblastine 
Taxol (Paclitaxel) Trastuzumab 
Abraxane (Paclitaxel Albumin-stabilized 
Nanoparticle Formulation) 
Cyclophosphamide 
Everolimus Everolimus Prednisone 
Afinitor (Everolimus) Gemcitabine 
Anastrozole Anastrozole Carboplatin 
Arimidex (Anastrozole) Megestrol acetate 
Exemestane Exemestane Rituximab 
Aromasin (Exemestane) Ixabepilone 
Capecitabine Capecitabine Cisplatin 
Xeloda (Capecitabine) Bevacizumab 
Cyclophosphamide Cyclophosphamide Ifosfamide 
Clafen (Cyclophosphamide) Triptorelin 
Cytoxan (Cyclophosphamide) Epirubicin 
Neosar (Cyclophosphamide) Exemestane 
Docetaxel Docetaxel Pemetrexed 
Taxotere (Docetaxel) Pamidronate 
Doxorubicin Hydrochloride Doxorubicin 
Hydrochloride 
Goserelin 
Epirubicin Hydrochloride Epirubicin 
Hydrochloride 
Lapatinib 
Ellence (Epirubicin Hydrochloride) Methotrexate 
Eribulin Mesylate Eribulin Mesylate Everolimus 
Halaven (Eribulin Mesylate) Mitomycin 
Pamidronate Disodium Pamidronate Disodium Docetaxel 
Aredia (Pamidronate Disodium) Leuprolide 
Toremifene Toremifene Trabectedin 
Fareston (Toremifene) Vinorelbine 
Fulvestrant Fulvestrant Fulvestrant 
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Faslodex (Fulvestrant) Mitoxantrone 
Letrozole Letrozole   
Femara (Letrozole)   
Fluorouracil Injection Fluorouracil Injection   
5-FU (Fluorouracil Injection)   
Gemcitabine Hydrochloride Gemcitabine 
Hydrochloride 
  
Gemzar (Gemcitabine Hydrochloride)   
Goserelin Acetate Goserelin Acetate   
Zoladex (Goserelin Acetate)   
Palbociclib Palbociclib   
Ibrance (Palbociclib)   
Ixabepilone Ixabepilone   
Ixempra (Ixabepilone)   
Ribociclib Ribociclib   
Kisqali (Ribociclib)   
Lapatinib Ditosylate Lapatinib Ditosylate   
Tykerb (Lapatinib Ditosylate)   
Olaparib Olaparib   
Lynparza (Olaparib)   
Megestrol Acetate Megestrol Acetate   
Neratinib Maleate Neratinib Maleate   
Nerlynx (Neratinib Maleate)   
Tamoxifen Citrate Tamoxifen Citrate   
Nolvadex (Tamoxifen Citrate)   
Pertuzumab Pertuzumab   
Perjeta (Pertuzumab)   
Thiotepa Thiotepa   
Trastuzumab Trastuzumab   
Kadcyla (Ado-Trastuzumab Emtansine)   
Herceptin (Trastuzumab)   
Ado-Trastuzumab Emtansine   
Vinblastine Sulfate Vinblastine Sulfate   
Velban (Vinblastine Sulfate)   
Velsar (Vinblastine Sulfate)   
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Supplement table 8 Treatment history of TCGA patients 
Disease 
Nr. Of patient 
with treatment 
history 
Nr. Of patient 
without treatment 
history 
Nr. Of patient with 
treatment history 
information is not 
available 
Breast Invasive Carcinoma 13 1079 2 
Glioblastoma Multiforme 21 568 1 
Ovarian Serous Cystadenocarcinoma 1 569 0 
Uterine Corpus Endometrial Carcinoma 2 538 0 
Renal Clear Cell Carcinoma 18 512 0 
Head and Neck Squamous Cell Carcinoma 9 508 0 
Brain Lower Grade Glioma 3 511 0 
Thyroid Carcinoma 5 500 0 
Lung Squamous Cell Carcinoma 7 496 0 
Prostate Adenocarcinoma 2 495 0 
Colon Adenocarcinoma 3 447 0 
Stomach Adenocarcinoma 0 442 0 
Bladder Urothelial Carcinoma 10 402 0 
Liver Hepatocellular Carcinoma 1 374 0 
Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma 
0 295 0 
Renal Papillary Cell Carcinoma 0 290 0 
Sarcoma 0 259 1 
Acute Myeloid Leukemia 38 105 0 
Esophageal Carcinoma 0 184 0 
Pancreatic Adenocarcinoma 1 183 0 
Pheochromocytoma and Paraganglioma 1 177 0 
Rectum Adenocarcinoma 1 163 0 
Testicular Germ Cell Tumors 0 134 0 
Thymoma 2 122 0 
Kidney Chromophobe 0 66 0 
Adrenocortical Carcinoma 1 89 0 
Mesothelioma 1 86 0 
Uveal Melanoma 0 80 0 
Lymphoid Neoplasm Diffuse Large B-cell 
Lymphoma 
1 47 0 
Uterine Carcinosarcoma 0 56 0 
Cholangiocarcinoma 1 35 0 
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Supplement table 9 Amplifications and deletions of genes annotated with various cancer 
hallmarks. For this, we annotated human genes following Suzuki et al [63] according to ten 
hallmarks of cancer: Activating Invasion and Metastasis, Resisting Cell Death, Evading 
Growth Suppressors, Avoiding Immune Destruction, Inducing Angiogenesis, Deregulating 
Cellular Energetics, Genome Instability and Mutation, Tumor Promoting Inflammation, 
Enabling Replicative Immortality, Sustaining Proliferative Signaling. For each hallmark, we 
retrieved the genes that were annotated by GO terms of the hallmark. We then checked the 
number of genes that were affected by amplifications and deletions. 
Hallmark p-value (Wilcoxon) p-value (T-test) 
Activating Invasion and Metastasis 2.41E-08 3.52E-09 
Resisting Cell Death 1.09E-08 1.50E-09 
Evading Growth Suppressors 5.37E-09 2.91E-10 
Avoiding Immune Destruction 0.00029905 0.000314 
Inducing Angiogenesis 1.72E-08 3.06E-09 
Deregulating Cellular Energetics 1.73E-07 6.77E-08 
Genome Instability and Mutation 2.36E-09 7.68E-11 
Tumor Promoting Inflammation 6.88E-09 1.27E-10 
Enabling Replicative Immortality 5.66E-08 4.99E-08 
Sustaining Proliferative Signaling 4.16E-08 9.16E-09 
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Supplement table 10 Number of cases when the specific AN targets were affected by CNAs. 
Disease 
Number 
of all 
cases 
Number 
of 
amplified 
cases 
Percentage 
of 
amplified  
cases 
Number 
of 
deleted 
cases 
Percentage 
of deleted 
cases 
Breast Invasive Carcinoma 1094 596 54.5% 662 60.5% 
Glioblastoma Multiforme 590 528 89.5% 170 28.8% 
Ovarian Serous Cystadenocarcinoma 570 316 55.4% 526 92.3% 
Uterine Corpus Endometrial 
Carcinoma 
540 0 0.00% 206 38.2% 
Renal Clear Cell Carcinoma 530 358 67.6% 468 88.3% 
Head and Neck Squamous Cell 
Carcinoma 
517 155 30.0% 321 62.1% 
Brain Lower Grade Glioma 514 147 28.6% 295 57.4% 
Thyroid Carcinoma 505 0 0.0% 0 0% 
Lung Squamous Cell Carcinoma 503 291 57.9% 349 69.4% 
Prostate Adenocarcinoma 497 0 0.0% 109 21.9% 
Colon Adenocarcinoma 450 81 18.0% 268 59.6% 
Stomach Adenocarcinoma 442 0 0.0% 128 29.0% 
Bladder Urothelial Carcinoma 412 196 47.6% 227 55.1% 
Liver Hepatocellular Carcinoma 375 0 0.0% 273 72.8% 
Cervical Squamous Cell Carcinoma 
and Endocervical Adenocarcinoma 
295 0 0.0% 182 61.7% 
Renal Papillary Cell Carcinoma 290 41 14.1% 91 31.4% 
Sarcoma 260 196 75.4% 225 86.5% 
Acute Myeloid Leukemia 143 0 0.0% 0 0% 
Esophageal Carcinoma 184 0 0.0% 146 79.4% 
Pancreatic Adenocarcinoma 184 40 21.7% 19 10.3% 
Pheochromocytoma and 
Paraganglioma 
178 0 0.0% 80 44.9% 
Rectum Adenocarcinoma 164 69 42.1% 0 0% 
Testicular Germ Cell Tumors 134 0 0% 0 0% 
Thymoma 124 0 0% 0 0% 
Kidney Chromophobe 66 0 0% 0 0% 
Adrenocortical Carcinoma 90 0 0% 60 66.7% 
Mesothelioma 87 0 0% 68 78.2% 
Uveal Melanoma 80 0 0% 0 0% 
Lymphoid Neoplasm Diffuse Large 
B-cell Lymphoma 
48 0 0% 17 35.4% 
Uterine Carcinosarcoma 56 0 0% 52 92.9% 
Cholangiocarcinoma 36 0 0% 0 0% 
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Supplement table 11 Pathways that have similar size with four AN resistance pathways 
Pathway ID Pathway name 
Number 
of 
genes 
path:hsa04260 Cardiac muscle contraction - Homo sapiens (human) 78 
path:hsa05220 Chronic myeloid leukemia - Homo sapiens (human) 78 
path:hsa00983 Drug metabolism - other enzymes - Homo sapiens (human) 79 
path:hsa01521 EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human) 79 
path:hsa03018 RNA degradation - Homo sapiens (human) 79 
path:hsa04610 Complement and coagulation cascades - Homo sapiens (human) 79 
path:hsa01522 Endocrine resistance - Homo sapiens (human) 96 
path:hsa04713 Circadian entrainment - Homo sapiens (human) 96 
path:hsa04925 Aldosterone synthesis and secretion - Homo sapiens (human) 96 
path:hsa04972 Pancreatic secretion - Homo sapiens (human) 96 
path:hsa05146 Amoebiasis - Homo sapiens (human) 96 
path:hsa00052 Galactose metabolism - Homo sapiens (human) 31 
path:hsa00410 beta-Alanine metabolism - Homo sapiens (human) 31 
path:hsa00512 Mucin type O-glycan biosynthesis - Homo sapiens (human) 31 
path:hsa01523 Antifolate resistance - Homo sapiens (human) 31 
path:hsa04710 Circadian rhythm - Homo sapiens (human) 31 
path:hsa05310 Asthma - Homo sapiens (human) 31 
path:hsa03320 PPAR signaling pathway - Homo sapiens (human) 72 
path:hsa04520 Adherens junction - Homo sapiens (human) 72 
path:hsa05210 Colorectal cancer - Homo sapiens (human) 72 
path:hsa05218 Melanoma - Homo sapiens (human) 72 
path:hsa05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) - Homo 
sapiens (human) 
72 
path:hsa00562 Inositol phosphate metabolism - Homo sapiens (human) 73 
path:hsa01524 Platinum drug resistance - Homo sapiens (human) 73 
path:hsa00980 Metabolism of xenobiotics by cytochrome P450 - Homo sapiens (human) 74 
path:hsa01230 Biosynthesis of amino acids - Homo sapiens (human) 74 
path:hsa04918 Thyroid hormone synthesis - Homo sapiens (human) 74 
path:hsa05140 Leishmaniasis - Homo sapiens (human) 74 
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Supplement table 12 adjusted p-values of Wilcoxon tests 
Pathway Amplification Deletion 
hsa04260 0.00003 1 
hsa05220 0.00001 1 
hsa00983 0.00073 1 
hsa01521 0.00009 1 
hsa03018 0.00014 1 
hsa04610 0.00199 1 
hsa01522 0.00001 0.76282 
hsa04713 0.01121 1 
hsa04925 0.00004 1 
hsa04972 0.00003 1 
hsa05146 0.00062 1 
hsa00052 1.00000 1 
hsa00410 0.00055 1 
hsa00512 0.14636 1 
hsa01523 0.02712 1 
hsa04710 0.03739 1 
hsa05310 0.06720 1 
hsa03320 0.00114 1 
hsa04520 0.00069 1 
hsa05210 0.00018 1 
hsa05218 0.00003 1 
hsa05412 0.00565 1 
hsa00562 0.00233 1 
hsa01524 0.00003 1 
hsa00980 0.00130 1 
hsa01230 0.00428 1 
hsa04918 0.00086 1 
hsa05140 0.00779 1 
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Supplement table 13: Treatment history of patients 
Disease 
Nr. of patients 
with treatment 
history 
Nr. of patients 
without treatment 
history 
Nr. of patients where 
treatment history 
information is not 
available 
Breast Invasive Carcinoma 13 1079 2 
Glioblastoma Multiforme 21 568 1 
Ovarian Serous Cystadenocarcinoma 1 569 0 
Uterine Corpus Endometrial Carcinoma 2 538 0 
Renal Clear Cell Carcinoma 18 512 0 
Head and Neck Squamous Cell Carcinoma 9 508 0 
Brain Lower Grade Glioma 3 511 0 
Thyroid Carcinoma 5 500 0 
Lung Squamous Cell Carcinoma 7 496 0 
Prostate Adenocarcinoma 2 495 0 
Colon Adenocarcinoma 3 447 0 
Stomach Adenocarcinoma 0 442 0 
Bladder Urothelial Carcinoma 10 402 0 
Liver Hepatocellular Carcinoma 1 374 0 
Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma 
0 295 0 
Renal Papillary Cell Carcinoma 0 290 0 
Sarcoma 0 259 1 
Acute Myeloid Leukemia 38 105 0 
Esophageal Carcinoma 0 184 0 
Pancreatic Adenocarcinoma 1 183 0 
Pheochromocytoma and Paraganglioma 1 177 0 
Rectum Adenocarcinoma 1 163 0 
Testicular Germ Cell Tumors 0 134 0 
Thymoma 2 122 0 
Kidney Chromophobe 0 66 0 
Adrenocortical Carcinoma 1 89 0 
Mesothelioma 1 86 0 
Uveal Melanoma 0 80 0 
Lymphoid Neoplasm Diffuse Large B-cell 
Lymphoma 
1 47 0 
Uterine Carcinosarcoma 0 56 0 
Cholangiocarcinoma 1 35 0 
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Supplement table 14 number of cancer types affect each gene in hsa10521 
Normal tissues Tumor tissues 
Amplification Deletion Amplification Deletion 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
PDGFRB 1 BAD 12 IGF1R 11 NRAS 19 
HGF 1 PDGFD 11 EGFR 9 FGFR2 14 
NRG2 1 RPS6KB2 11 PIK3CA 7 PDGFD 12 
EIF4E1B 1 KDR 10 GAS6 7 FOXO3 11 
SOS1 1 HRAS 10 VEGFA 7 PIK3CD 10 
EIF4E2 1 PDGFRA 10 KRAS 7 AKT1 10 
MET 1 FGF2 9 FGFR3 6 EIF4E1B 10 
PDGFA 1 JAK1 9 AKT3 5 HRAS 9 
TGFA 1 GAB1 9 PDGFA 5 JAK1 9 
PIK3R1 1 EIF4E1B 9 AKT1 4 NRG1 9 
EGFR 1 SOS1 9 JAK2 4 PIK3R1 9 
BCL2L11 1 EIF4E2 9 PRKCG 4 MTOR 9 
PLCG2 1 TGFA 9 PDGFRA 4 PTEN 8 
MAPK1 1 BCL2L11 9 PRKCA 4 AKT3 8 
BRAF 1 PDGFC 9 GRB2 4 EIF4E2 8 
IL6 1 EIF4E 9 EIF4E1B 3 ERBB3 8 
GSK3B 0 EGF 9 MET 3 BAD 8 
ARAF 0 FGFR3 9 KDR 2 BRAF 8 
PTEN 0 PDGFRB 8 IL6R 2 BCL2 8 
PIK3CD 0 NRG2 8 GAB1 2 FGF2 7 
PIK3CB 0 IL6R 7 SHC1 2 SHC4 7 
FGF2 0 SHC1 7 PDGFC 2 EIF4E 7 
IGF1R 0 PIK3R3 7 STAT3 2 KRAS 7 
AKT2 0 PIK3R1 7 NF1 2 PDGFRB 6 
AKT3 0 NRAS 7 PIK3CD 1 MAP2K2 6 
KDR 0 NF1 7 PIK3CB 1 GAS6 6 
AKT1 0 PIK3CD 6 FGF2 1 PIK3R3 6 
JAK2 0 AKT3 6 MAP2K1 1 PDGFC 6 
HRAS 0 ERBB2 6 HGF 1 EIF4EBP1 6 
IL6R 0 STAT3 6 SHC2 1 PLCG2 6 
JAK1 0 MTOR 6 SHC3 1 VEGFA 6 
PRKCG 0 GSK3B 5 PIK3R2 1 RPS6KB2 6 
PDGFRA 0 PTEN 5 FOXO3 1 IL6R 5 
MAP2K1 0 PIK3CB 5 NRAS 1 PRKCG 5 
MAP2K2 0 JAK2 5 BCL2L11 1 NRG2 5 
PRKCB 0 NRG1 5 ERBB2 1 RAF1 5 
RPS6 0 PRKCA 5 EIF4EBP1 1 SOS2 5 
GAB1 0 FOXO3 5 MAPK1 1 SHC2 5 
NRG1 0 ERBB3 5 BRAF 1 SHC1 5 
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PRKCA 0 EIF4EBP1 5 MTOR 1 EGF 5 
PIK3CA 0 IGF1 5 RPS6KB2 1 GSK3B 4 
GAS6 0 RPS6KB1 5 BAX 1 PIK3CB 4 
RAF1 0 BCL2 5 FGFR2 1 JAK2 4 
SOS2 0 GRB2 5 GSK3B 0 PIK3CA 4 
SHC4 0 FGFR2 5 ARAF 0 SHC3 4 
SHC2 0 HGF 4 PTEN 0 PDGFA 4 
SHC3 0 PIK3CA 4 AKT2 0 PIK3R2 4 
SHC1 0 RAF1 4 HRAS 0 STAT3 4 
SRC 0 MET 4 JAK1 0 IGF1 4 
PDGFB 0 PDGFA 4 PDGFRB 0 BAX 4 
PIK3R3 0 EGFR 4 MAP2K2 0 AKT2 3 
PIK3R2 0 BRAF 4 PRKCB 0 GAB1 3 
FOXO3 0 VEGFA 4 RPS6 0 SOS1 3 
NRAS 0 IL6 4 NRG1 0 MET 3 
ERBB3 0 KRAS 4 NRG2 0 SRC 3 
PDGFD 0 RPS6 3 RAF1 0 ERBB2 3 
ERBB2 0 SHC3 3 SOS1 0 PLCG1 3 
PDGFC 0 PDGFB 3 EIF4E2 0 AXL 3 
EIF4EBP1 0 MAPK1 3 SOS2 0 GRB2 3 
PLCG1 0 BCL2L1 3 SHC4 0 BCL2L1 3 
EIF4E 0 IGF1R 2 SRC 0 IGF1R 2 
MAPK3 0 AKT2 2 PDGFB 0 KDR 2 
EGF 0 AKT1 2 TGFA 0 PDGFRA 2 
BAD 0 PRKCG 2 PIK3R3 0 PRKCB 2 
STAT3 0 MAP2K1 2 PIK3R1 0 RPS6 2 
IGF1 0 MAP2K2 2 ERBB3 0 PDGFB 2 
MTOR 0 GAS6 2 PDGFD 0 MAPK3 2 
VEGFA 0 SOS2 2 PLCG2 0 MAP2K1 1 
RPS6KB1 0 SHC4 2 PLCG1 0 TGFA 1 
AXL 0 SHC2 2 EIF4E 0 RPS6KB1 1 
RPS6KB2 0 SRC 2 MAPK3 0 NF1 1 
NF1 0 PIK3R2 2 EGF 0 ARAF 0 
BCL2 0 PLCG1 2 BAD 0 HGF 0 
BAX 0 AXL 2 IGF1 0 PRKCA 0 
GRB2 0 BAX 2 IL6 0 EGFR 0 
KRAS 0 PRKCB 1 RPS6KB1 0 BCL2L11 0 
FGFR3 0 PLCG2 1 AXL 0 MAPK1 0 
FGFR2 0 MAPK3 1 BCL2 0 IL6 0 
BCL2L1 0 ARAF 0 BCL2L1 0 FGFR3 0 
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Supplement table 15 number of cancer types affect each gene in hsa10522 
Normal tissues Tumor tissues 
Amplification Deletion Amplification Deletion 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
SOS1 1 BAD 12 IGF1R 11 CDKN2A 21 
HBEGF 1 CCND1 11 EGFR 9 NRAS 19 
ADCY3 1 RPS6KB2 11 MDM2 9 PRKACB 16 
ADCY2 1 HRAS 10 PIK3CA 7 MAPK12 15 
ADCY1 1 SOS1 9 KRAS 7 MAPK11 15 
PIK3R1 1 ADCY3 9 AKT3 5 DLL4 14 
ABCB11 1 ABCB11 9 AKT1 4 RB1 13 
EGFR 1 MAPK10 9 MMP9 4 CDKN1B 12 
MAPK9 1 PRKACB 8 NOTCH3 4 NOTCH2 12 
MAPK1 1 HBEGF 8 PTK2 4 PIK3CD 10 
BRAF 1 JUN 8 GRB2 4 AKT1 10 
RB1 0 NOTCH2 7 NOTCH2 3 FOS 10 
CDKN1A 0 SHC1 7 ADCY8 3 DLL1 10 
CDKN1B 0 PIK3R3 7 MAPK9 3 MAPK8 10 
ARAF 0 ADCY2 7 GNAS 3 E2F2 10 
PIK3CD 0 PIK3R1 7 SHC1 2 JAG2 10 
PIK3CB 0 MAPK9 7 ADCY4 2 ESR2 10 
IGF1R 0 NRAS 7 JAG2 2 HRAS 9 
CCND1 0 CDKN2C 7 CDKN1A 1 ADCY4 9 
CYP2D6 0 PIK3CD 6 PIK3CD 1 PIK3R1 9 
AKT2 0 AKT3 6 PIK3CB 1 ADCY6 9 
GPER1 0 MED1 6 CCND1 1 MAPK9 9 
PRKACG 0 NCOR1 6 PRKACG 1 MTOR 9 
AKT3 0 ERBB2 6 PRKACB 1 AKT3 8 
AKT1 0 E2F2 6 MED1 1 BAD 8 
PRKACA 0 MTOR 6 MAP2K1 1 BRAF 8 
HRAS 0 PIK3CB 5 FOS 1 SP1 8 
PRKACB 0 TP53 5 SHC2 1 BCL2 8 
MED1 0 ADCY8 5 NOTCH1 1 SHC4 7 
MAP2K1 0 ADCY6 5 SHC3 1 JUN 7 
MAP2K2 0 ADCY5 5 PIK3R2 1 CDKN2C 7 
MMP2 0 MAPK8 5 ADCY1 1 CDK4 7 
NCOA3 0 IGF1 5 ABCB11 1 MDM2 7 
FOS 0 RPS6KB1 5 DLL1 1 KRAS 7 
MMP9 0 CDK4 5 NRAS 1 CCND1 6 
ADCY9 0 SP1 5 ERBB2 1 PRKACG 6 
NCOR1 0 MDM2 5 E2F1 1 MAP2K2 6 
null * 0 BCL2 5 MAPK1 1 PIK3R3 6 
PIK3CA 0 GRB2 5 E2F3 1 E2F3 6 
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RAF1 0 CDKN1A 4 JUN 1 ESR1 6 
SOS2 0 CDKN1B 4 JAG1 1 RPS6KB2 6 
TP53 0 PIK3CA 4 BRAF 1 CDKN1A 5 
SHC4 0 RAF1 4 MAPK14 1 RAF1 5 
NOTCH2 0 ADCY1 4 MTOR 1 SOS2 5 
NOTCH3 0 EGFR 4 RPS6KB2 1 HBEGF 5 
SHC2 0 BRAF 4 BAX 1 SHC2 5 
NOTCH1 0 MAPK14 4 RB1 0 SHC1 5 
SHC3 0 PTK2 4 CDKN1B 0 NOTCH4 5 
SHC1 0 MAPK13 4 ARAF 0 ADCY3 5 
SRC 0 KRAS 4 CYP2D6 0 ADCY7 5 
NOTCH4 0 CYP2D6 3 AKT2 0 BIK 5 
ADCY4 0 PRKACG 3 GPER1 0 MAPK14 5 
PIK3R3 0 NOTCH1 3 PRKACA 0 MAPK13 5 
PIK3R2 0 SHC3 3 HRAS 0 MAPK10 5 
ADCY8 0 NOTCH4 3 MAP2K2 0 PIK3CB 4 
ADCY7 0 DLL1 3 MMP2 0 CYP2D6 4 
DLL1 0 MAPK1 3 NCOA3 0 PIK3CA 4 
ADCY6 0 E2F3 3 ADCY9 0 SHC3 4 
DLL3 0 CDKN2A 3 NCOR1 0 PIK3R2 4 
ADCY5 0 BIK 3 null 0 ADCY5 4 
DLL4 0 ESR1 3 RAF1 0 IGF1 4 
NRAS 0 ESR2 3 SOS1 0 PTK2 4 
MAPK8 0 MAPK12 3 SOS2 0 BAX 4 
ERBB2 0 MAPK11 3 TP53 0 AKT2 3 
E2F1 0 RB1 2 HBEGF 0 PRKACA 3 
E2F2 0 IGF1R 2 SHC4 0 MED1 3 
E2F3 0 AKT2 2 SRC 0 MMP2 3 
MAPK3 0 AKT1 2 NOTCH4 0 NCOA3 3 
JAG2 0 PRKACA 2 ADCY3 0 MMP9 3 
JUN 0 MAP2K1 2 PIK3R3 0 SOS1 3 
CDKN2C 0 MAP2K2 2 ADCY2 0 NOTCH3 3 
JAG1 0 NCOA3 2 PIK3R1 0 SRC 3 
CDKN2A 0 FOS 2 ADCY7 0 ADCY8 3 
BAD 0 MMP9 2 ADCY6 0 ABCB11 3 
BIK 0 SOS2 2 DLL3 0 DLL3 3 
IGF1 0 SHC4 2 ADCY5 0 ERBB2 3 
MAPK14 0 NOTCH3 2 DLL4 0 E2F1 3 
ESR1 0 SHC2 2 MAPK8 0 JAG1 3 
ESR2 0 SRC 2 E2F2 0 CARM1 3 
MTOR 0 ADCY4 2 MAPK3 0 GNAS 3 
PTK2 0 PIK3R2 2 CDKN2C 0 GRB2 3 
MAPK12 0 DLL3 2 CDKN2A 0 IGF1R 2 
MAPK13 0 DLL4 2 BAD 0 TP53 2 
MAPK10 0 E2F1 2 BIK 0 NOTCH1 2 
MAPK11 0 JAG2 2 IGF1 0 MAPK3 2 
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RPS6KB1 0 JAG1 2 ESR1 0 MAP2K1 1 
CDK4 0 CARM1 2 ESR2 0 ADCY9 1 
SP1 0 GNAS 2 MAPK12 0 NCOR1 1 
CARM1 0 BAX 2 MAPK13 0 ADCY2 1 
RPS6KB2 0 MMP2 1 MAPK10 0 RPS6KB1 1 
GNAS 0 ADCY9 1 MAPK11 0 ARAF 0 
MDM2 0 ADCY7 1 RPS6KB1 0 GPER1 0 
BCL2 0 MAPK3 1 CDK4 0 null 0 
BAX 0 ARAF 0 SP1 0 ADCY1 0 
GRB2 0 GPER1 0 CARM1 0 EGFR 0 
KRAS 0 null 0 BCL2 0 MAPK1 0 
  
* null indicates that the gene in KEGG pathway has no corresponding gene symbol  
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Supplement table 16 number of cancer types affect each gene in hsa10523 
Normal tissues Tumor tissues 
Amplification Deletion Amplification Deletion 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
ATIC 1 RELA 11 IKBKB 6 ABCC2 13 
DHFR 1 FOLR3 11 ABCC5 4 CHUK 13 
IL6 1 FOLR2 11 TYMS 3 MTHFR 9 
IL1B 1 FOLR1 11 GGH 3 SLC46A1 7 
SLC46A1 0 ATIC 9 ABCC4 2 SHMT2 7 
DHFR2 0 NFKB1 9 SLC46A1 1 RELA 7 
SHMT2 0 IL1B 9 SHMT1 1 ABCC4 7 
SHMT1 0 ABCG2 9 MTHFR 1 NFKB1 7 
ALOX12 0 SLC46A1 7 IL1B 1 DHFR 7 
TYMS 0 DHFR 7 DHFR2 0 FOLR3 7 
TNF 0 SHMT1 6 SHMT2 0 FOLR2 7 
RELA 0 MTHFR 6 ALOX12 0 FOLR1 7 
IKBKB 0 SHMT2 5 TNF 0 IKBKB 6 
FPGS 0 ALOX12 5 RELA 0 SLC19A1 6 
IKBKG 0 TYMS 5 ATIC 0 TNF 5 
SLC19A1 0 IKBKB 5 FPGS 0 ATIC 5 
ABCC3 0 ABCC3 5 IKBKG 0 GGH 5 
ABCC4 0 ABCC2 5 SLC19A1 0 ABCG2 5 
ABCC1 0 CHUK 5 ABCC3 0 TYMS 3 
ABCC2 0 GGH 5 ABCC1 0 ABCC5 3 
CHUK 0 ABCC5 4 ABCC2 0 ALOX12 2 
ABCC5 0 IL6 4 CHUK 0 FPGS 2 
MTHFR 0 TNF 3 IZUMO1R 0 ABCC3 1 
GGH 0 FPGS 3 NFKB1 0 ABCC1 1 
IZUMO1R 0 ABCC4 2 DHFR 0 GART 1 
NFKB1 0 ABCC1 1 IL6 0 DHFR2 0 
FOLR3 0 DHFR2 0 FOLR3 0 SHMT1 0 
FOLR2 0 IKBKG 0 FOLR2 0 IKBKG 0 
FOLR1 0 SLC19A1 0 FOLR1 0 IZUMO1R 0 
GART 0 IZUMO1R 0 GART 0 IL6 0 
ABCG2 0 GART 0 ABCG2 0 IL1B 0 
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Supplement table 17 number of cancer types affect each gene in hsa10524 
Normal tissues Tumor tissues 
Amplification Deletion Amplification Deletion 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
Genes 
Number of 
diseases 
CASP8 1 BAD 12 MDM2 9 CDKN2A 21 
MSH6 1 BIRC2 11 PIK3CA 7 GSTO2 16 
MSH2 1 BIRC3 11 FASLG 5 GSTO1 16 
MSH3 1 GSTP1 11 AKT3 5 ATM 16 
PIK3R1 1 FADD 11 POLH 5 GSTM4 15 
MAPK1 1 ATM 11 AKT1 4 GSTM3 15 
BID 1 CASP8 9 BIRC5 4 GSTM2 15 
CYCS 1 CASP3 9 MGST3 4 GSTM1 15 
TOP2A 0 MSH6 9 BID 4 GSTM5 15 
TOP2B 0 MSH2 9 BIRC2 3 ABCC2 13 
CDKN1A 0 MGST2 9 BIRC3 3 PIK3CD 10 
PIK3CD 0 GSTM4 8 GSTP1 3 REV3L 10 
FASLG 0 GSTM3 8 GSTA5 3 AKT1 10 
PIK3CB 0 GSTM2 8 GSTA4 3 CASP3 9 
BRCA1 0 GSTM1 8 GSTA3 3 MGST1 9 
BBC3 0 GSTM5 8 GSTA2 3 PIK3R1 9 
CASP9 0 FASLG 7 GSTA1 3 CASP9 8 
ATP7B 0 MSH3 7 TOP2A 2 ATP7B 8 
AKT2 0 MGST3 7 CASP3 2 AKT3 8 
CASP3 0 PIK3R3 7 MGST2 2 BIRC2 8 
AKT3 0 PIK3R1 7 FADD 2 BIRC3 8 
REV3L 0 TOP2A 6 CDKN1A 1 BAD 8 
AKT1 0 PIK3CD 6 PIK3CD 1 BCL2 8 
ATP7A 0 BRCA1 6 PIK3CB 1 MAP3K5 7 
POLH 0 CASP9 6 CASP8 1 MSH3 7 
MAP3K5 0 AKT3 6 REV3L 1 GSTA5 7 
ABCC2 0 GSTO2 6 MAP3K5 1 GSTA4 7 
GSTO2 0 GSTO1 6 MSH6 1 GSTA3 7 
APAF1 0 ERBB2 6 MSH2 1 GSTA2 7 
PDPK1 0 PIK3CB 5 MGST1 1 GSTA1 7 
GSTO1 0 REV3L 5 XPA 1 MDM2 7 
PIK3CA 0 ABCC2 5 GSTT2 1 FAS 7 
BIRC5 0 APAF1 5 GSTT1 1 BBC3 6 
TP53 0 BIRC5 5 PIK3R2 1 POLH 6 
BIRC2 0 TP53 5 ERBB2 1 APAF1 6 
BIRC3 0 PMAIP1 5 MAPK1 1 GSTP1 6 
GSTP1 0 MDM2 5 GSTT2B 1 MGST3 6 
MGST3 0 BCL2 5 GSTM4 1 PIK3R3 6 
MGST1 0 FAS 5 GSTM3 1 FADD 6 
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XPA 0 TOP2B 4 GSTM2 1 CDKN1A 5 
GSTT2 0 CDKN1A 4 GSTM1 1 FASLG 5 
XIAP 0 POLH 4 ERCC1 1 PMAIP1 5 
MGST2 0 PIK3CA 4 BAX 1 BAK1 5 
PIK3R3 0 MGST1 4 GSTM5 1 PIK3CB 4 
GSTT1 0 MLH1 4 TOP2B 0 BRCA1 4 
PIK3R2 0 GSTA5 4 BRCA1 0 PIK3CA 4 
ERBB2 0 GSTA4 4 BBC3 0 PIK3R2 4 
PMAIP1 0 GSTA3 4 CASP9 0 BAX 4 
BAK1 0 GSTA2 4 ATP7B 0 TOP2A 3 
FADD 0 GSTA1 4 AKT2 0 TOP2B 3 
GSTT2B 0 CYCS 4 ATP7A 0 AKT2 3 
MAPK3 0 MAP3K5 3 ABCC2 0 MSH6 3 
GSTM4 0 XPA 3 GSTO2 0 MSH2 3 
GSTM3 0 GSTT2 3 APAF1 0 MGST2 3 
GSTM2 0 GSTT1 3 PDPK1 0 ERBB2 3 
GSTM1 0 MAPK1 3 GSTO1 0 ERCC1 3 
CDKN2A 0 BAK1 3 MSH3 0 BCL2L1 3 
SLC31A1 0 BID 3 TP53 0 CASP8 2 
BAD 0 GSTT2B 3 XIAP 0 BIRC5 2 
MLH1 0 CDKN2A 3 PIK3R3 0 TP53 2 
GSTA5 0 SLC31A1 3 PIK3R1 0 XPA 2 
GSTA4 0 BCL2L1 3 PMAIP1 0 MAPK3 2 
GSTA3 0 BBC3 2 BAK1 0 MLH1 2 
ERCC1 0 ATP7B 2 MAPK3 0 PDPK1 1 
GSTA2 0 AKT2 2 CDKN2A 0 BID 1 
GSTA1 0 AKT1 2 SLC31A1 0 ATP7A 0 
MDM2 0 PDPK1 2 BAD 0 GSTT2 0 
BCL2 0 PIK3R2 2 MLH1 0 XIAP 0 
FAS 0 ERCC1 2 BCL2 0 GSTT1 0 
BAX 0 BAX 2 FAS 0 MAPK1 0 
ATM 0 MAPK3 1 CYCS 0 GSTT2B 0 
GSTM5 0 ATP7A 0 ATM 0 SLC31A1 0 
BCL2L1 0 XIAP 0 BCL2L1 0 CYCS 0 
 
